Formulation Development and Evaluation of Ketoprofen Buccal Tablets by Kartheeswaran, M
  
 
FORMULATION DEVELOPMENT AND EVALUATION OF 
KETOPROFEN BUCCAL TABLETS 
 
 
Dissertation submitted to 
 
THE TAMILNADU DR. M.G.R. MEDICAL UNIVERSITY, CHENNAI-32 
 
 
In partial fulfillment for the award of the degree of 
 
MASTER OF PHARMACY 
IN 
PHARMACEUTICS 
 
Submitted by 
 
Register Number: 26111007 
 
Under the guidance of 
Mr. D. Kalyanasundaram, B.Pharm.,    DR. R. Kumaravel Rajan, M.Pharm., Ph.D., 
(Industrial Guide)                                    (Institutional Guide) 
 
 
DEPARTMENT OF PHARMACEUTICS 
C.L.BAID METHA COLLEGE OF PHARMACY 
(AN ISO 9001-2000 certified institute) 
THORAIPAKKAM, CHENNAI-600097 
 
APRIL-2013 
 
  
 
  
 
THE CERTIFICATE 
 
                    This is to certify that the dissertation work entitled “FORMULATION 
DEVELOPMENT AND EVALUATION OF KETOPROFEN BUCCAL 
TABLETS” submitted to THE TAMILNADU DR. M.G.R. MEDICAL 
UNIVERSITY, CHENNAI-32 for the award of the degree of Master of Pharmacy in 
Pharmaceutics is a bonafide research work done by Register Number: 26111007 
under my Guidance in the Department of Pharmaceutics, C.L. Baid Metha College of 
Pharmacy, Chennai-600097 during the academic year 2012-2013. 
 
 
 
Place: Chennai-97.                                          
Date:                                                                              
 
 
   
  
  
 
THE CERTIFICATE 
             This is to certify that the dissertation work entitled “FORMULATION 
DEVELOPMENT AND EVALUATION OF KETOPROFEN BUCCAL 
TABLETS” submitted to THE TAMILNADU DR. M.G.R. MEDICAL 
UNIVERSITY, CHENNAI-32 for the award of the degree of Master of Pharmacy in 
Pharmaceutics is a bonafide research work done by Register Number: 26111007 
under  the  guidance of DR. R. Kumaravel Rajan M.Pharm., Ph.D., Assistant 
Professor, Department of Pharmaceutics, C. L. Baid Metha college of Pharmacy, 
Chennai-600097 during the academic year 2012-2013. 
 
 
 
Place: Chennai -97.      DR. Grace Rathnam, M. Pharm., Ph.D.,  
Date:  Principal  & HOD,   
  Department of Pharmaceutics, 
  C.L.Baid Metha College of Pharmacy, 
  Chennai-97. 
 
  
  
DECLARATION 
 
                    I hereby declare that the thesis entitled “FORMULATION 
DEVELOPMENT AND EVALUATION OF KETOPROFEN BUCCAL 
TABLETS” has been originally carried out by me under the supervision and guidance 
of Mr. D. Kalyanasundaram, B.Pharm., (Industrial Guide) and DR. R. Kumaravel 
Rajan, M.Pharm., Ph.D., (Institutional Guide) Asst. Professor, Department of 
Pharmaceutics, C.L.Baid Metha College of Pharmacy, Chennai-97, during the academic 
year 2012-2013.  
 
 
 
 
 
Place: Chennai-97.    Register Number: 26111007, 
Date:                                                           Department of Pharmaceutics, 
          C. L. Baid Metha College of Pharmacy, 
Chennai-97. 
 
 
 
 
 
 
  
ACKNOWLEDGEMENT 
 
 I take great pleasure in acknowledging those, without whom, this work would 
not have been completed. 
 First of all, I would like to express my deep sense of gratitude to my  respected  
guide  DR. R. Kumaravel Rajan, M. Pharm., Ph.D., Assistant Professor, C. L. Baid  
Metha College of Pharmacy,Chennai-97 for his guidance and constant encouragement to 
strife better throughout  the  course  of  this investigation. 
 The immense help I received from my industrial guide  
Mr. D. Kalyanasundaram, B.Pharm., cannot be discounted by any means and I would 
like to thank him for his valuable guidance and support in each and every aspect of the 
project. 
The seeds of the project were long sown in my mind by                                    
DR. Grace Rathnam M.Pharm, Ph.D., (Principal cum HOD Dept. of  Pharmaceutics) 
for which I thank her whole heartedly. 
 I would like to extend the my gratitude to Mr. M. Lakshmanan, B.Pharm., 
(Managing  Partner – M/s Pharmafabrikon, Madurai)for providing the great 
opportunity of carrying out my project work at Pharmafabrikon Unit-II, Madurai. I 
would also like to thank the staff of Pharmafabrikon Unit-II, Madurai for their 
support and co-operation during my work there. 
I thank all the Teaching and Non-teaching Staff members of C.L. Baid Metha 
College of Pharmacy, Chennai-97for their support. 
I thank all my Friends, for without them this project would have not seen the 
light of day. 
  
  
 
Last but not least, I acknowledge the support of my Family in every endeavour I 
take. No amount of gratitude can ever equal the support they have given me and for this 
I remain eternally in their debt. 
  
(Reg.No.26111007) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
DEDICATED 
TO 
MY FAMILY 
 
 i 
 
ABBREVIATIONS 
 
API Active Pharmaceutical Ingredient 
BCS Biopharmaceutical Classification System 
BP British Pharmacopoeia 
DC Direct Compression 
DSC Differential Scanning Calorimeter 
GIT Gastro Intestinal Tract 
HPMC Hydroxy Propyl Methyl Cellulose 
IP Indian Pharmacopoeia 
IPA Isopropyl Alcohol  
MCC Micro Crystalline Cellulose 
NSAIDs Non-Steroidal Anti-Inflammatory Drugs 
PVP Poly Vinyl Pyrrolidone  
USP United States Pharmacopoeia 
WG Wet Granulation 
 
 
NOMENCLATURE 
 
dave Average diameter 
C Celsius 
cm Centimetre 
° Degree 
g Gram  
h Hour/s 
Kp Kilo pound 
µm Micro meter 
µg Microgram 
mg Milligram 
ml Millilitre 
mm Millimetre 
Min Minutes 
Pa Pascal 
% Percentage 
w Weight 
 
 
 
 ii 
 
 
CONTENTS 
 
 
 
Chapter No. Title Page No. 
1 Introduction 1 
1.1 Mucoadhesive drug delivery system 1 
1.2 Bioadhesion 2 
1.3 Oral Mucosa 4 
1.4 Buccoadhesive Dosage Forms 6 
1.5 Buccal Tablets 7 
1.6 Optimization 9 
1.7 Optimization techniques in pharmaceutical industry 9 
1.8 Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) 10 
2 Literature Review 12 
3 Aim and Objectives 20 
4 Plan of Work 21 
4.1 Flow of work 21 
5 Drug and Excipient Profile 22 
5.1 Ketoprofen 22 
5.2 Excipient Profile 25 
6 Materials and Methodology 37 
6.1 Materials and Equpiments 37 
6.2 Methodology 39 
7 Results and Discussions 47 
7.1 Results 47 
7.2 Discussions 67 
8 Summary 70 
9 Conclusion 71 
 iii 
 
 
 
LIST OF TABLES 
 
Table No. Title Page No. 
Table 1.1  Marketed buccal tablets 9 
Table 4.1  Application of HPMC at various concentrations 26 
Table 4.2  Properties of HPMC 26 
Table 4.3  HPMC viscosity grades 27 
Table 4.4  Applications of MCC at different concentrations 29 
Table 4.5  Properties of MCC PH 112 29 
Table 4.6  Pharmaceutical applications of PVP 30 
Table 4.7  Physical properties of PVP 31 
Table 4.8  Properties of IPA 36 
Table 4.9  List of materials and their application in the formulation 37 
Table 4.10  List of instruments and equipments 38 
Table 4.11  Levels of Independent Variables 39 
Table 4.12  Experimental design based on key parameters 39 
Table 4.13  Formulations prepared by direct compression method 40 
Table 4.14  Formulations prepared by wet granulation method 41 
Table 4.15  Limits for Tablet Weight Variation 42 
Table 4.16  Release mechanisms based on n-value 45 
Table 4.17  Parameters of release kinetics 46 
Table 7.1  Uniformity of Weight 48 
Table 7.2  Average thickness of the Ketoprofen buccal tablets 49 
Table 7.3  Average hardness of the Ketoprofen buccal tablets 50 
  
 iv 
 
 
 
Table No. Title Page No. 
Table 7.4  % Friability of the Ketoprofen buccal tablets 51 
Table 7.5  Absorbance of standard solutions of Ketoprofen 51 
Table 7.6 
 Assay values (%) and drug contents (mg) of the Ketoprofen 
buccal tablets 
52 
Table 7.7  Swelling index of the Ketoprofen buccal tablets 53 
Table 7.8  Time duration of attachment of the Ketoprofen buccal tablets 54 
Table 7.9 
 In vitro drug release profile of Ketoprofen buccal tablet 
formulations 1-4 
55 
Table 7.10 
 In vitro drug release profile of Ketoprofen buccal tablet 
formulations 5-8 
56 
Table 7.11 
 In vitro drug release profile of Ketoprofen buccal tablet 
formulations 9-12 
57 
Table 7.12 
 In vitro drug release profile of Ketoprofen buccal tablet 
formulations 13-16 
58 
Table 7.13 
 Ex vivo drug permeation data for Ketoprofen buccal tablet 
formulations 1-4 
59 
Table 7.14 
 Ex vivo drug permeation data for Ketoprofen buccal tablet 
formulations 5-8 
60 
Table 7.15 
 Ex vivo drug permeation data for Ketoprofen buccal tablet 
formulations 9-12 
61 
Table 7.16 
 Ex vivo drug permeation data for Ketoprofen buccal tablet 
formulations 13-16 
62 
Table 7.17  Ketoprofen release kinetics and mechanisms 63 
Table 7.18  Parameters of optimized formulation 66 
 
 
 
 
 
 
 
 v 
 
LIST OF FIGURES 
 
Figure No. Caption Page No. 
Figure 1.1  Structure of the oral mucosa 5 
Figure 1.2 
 Schematic representation of different matrix tablets for buccal 
delivery                        
8 
Figure 4.1  Schematics of plan of work 21 
Figure 7.1  Overlay of DSC profiles of drug and polymers 47 
Figure 7.2  Uniformity of Weight 48 
Figure 7.3  Average thickness of the Ketoprofen buccal tablets 49 
Figure 7.4  Average hardness of the Ketoprofen buccal tablets 50 
Figure 7.5  Standard plot for Ketoprofen @ pH 6.8 52 
Figure 7.6  Swelling index of the Ketoprofen buccal tablets 53 
Figure 7.7  Time duration of attachment of the Ketoprofen buccal tablets 54 
Figure 7.8 
 In vitro dissolution profiles of Ketoprofen buccal tablet 
formulations 1-4 
55 
Figure 7.9 
 In vitro dissolution profiles of Ketoprofen buccal tablet 
formulations 5-8 
56 
Figure 7.10 
 In vitro dissolution profiles of Ketoprofen buccal tablet 
formulations 9-12 
57 
Figure 7.11 
 In vitro dissolution profiles of Ketoprofen buccal tablet 
formulations 13-16 
58 
Figure 7.12 
 Ex vivo drug permeation for Ketoprofen buccal tablet 
formulations 1-4 
59 
Figure 7.13 
 Ex vivo drug permeation for Ketoprofen buccal tablet 
formulations 5-8 
60 
Figure 7.14 
 Ex vivo drug permeation for Ketoprofen buccal tablet 
formulations 9-12 
61 
Figure 7.15 
 Ex vivo drug permeation for Ketoprofen buccal tablet 
formulations 13-16 
62 
Figure 7.16  R2 values of release kinetics and mechanisms 63 
Figure 7.17  Plot of predicted value (vs) actual value for wash-off time 64 
Figure 7.18  Plot of predicted value (vs) actual value for Ex vivo permeation 65 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
INTRODUCTION 
 
 
 
 
 
 
 
 
 
 
 
  
1 
1 Introduction 
The process of drug discovery is tedious, involving a vast amount of capital 
expenditure, time, and man power. It is further constrained by the various rules and 
regulations put in place to ensure that human ethics is not compromised. This 
hasresulted in the decline in the number of newer molecules being introduced into the 
market. The checks although restrictive are necessary to avoid incidents such as the 
‘Thalidomide Tragedy’. Recently, many drugs, Rosiglitazone, Nimesulide (banned in 
the US and European Union), Valdecoxib, etc… to name a few, have been withdrawn 
from the market because of the severity of their adverse effects, several of which are 
fatal. 
The decline in the development of new drug molecules can be compensated to an 
extent with the adoption of novel delivery systems for the drugs that are currently in the 
market to enhance their efficacy and lower/minimize their adverse effects. 
1.1 Mucoadhesive drug delivery system 
One such novel drug delivery system is the mucoadhesive drug delivery system. 
Investigation regarding the mucoadhesive system began in the 1980’s itself(1). Yet this 
field is still considered to be in its infancy because of the slow rate of adoption of the 
technology in the market and industries
(2)
.    
Dosage forms designed for mucoadhesive drug delivery should be small and 
flexible enough to be acceptable for patients and should not cause irritation. Other 
desired characteristics of a mucoadhesive dosage form include high drug loading 
capacity, controlled drug release (preferably unidirectional release), good mucoadhesive 
properties, smooth surface, tastelessness, and convenient application. Bio-erodible 
formulations containing thermoplastic polymers can be beneficial because they do not 
require system retrieval at the end of desired dosing interval
(2)
. A number of relevant 
mucoadhesive dosage forms have been developed for a variety of drugs. Several 
peptides, including Thyrotropin-Releasing Hormone (TRH), Insulin
(2)
, Octreotide, 
Oeuprolide, and Oxytocin, have been delivered via the mucosal route, albeit with 
relatively low bioavailability (0.1–5%),owing to their hydrophilicity and large molecular 
weight, as well as the inherent permeation and enzymatic barriers of the mucosa. 
 
 
  
2 
1.2 Bioadhesion 
Bio-adhesion can be defined as a state in which two components, of which one is 
biological in origin, are held together for extended periods of time by the help of 
interfacial forces. It isdenoted (esp. in pharmacy) as mucoadhesion since the main 
biomaterial involved is mucus present at various sites in the body
(3)
. 
The mechanisms involved in bio-adhesion are
(1)(4)
: 
 The  formation  of a double-layer  of electrical  charge  as a result  of  
electron  transfer  across  an  interface – electronic theory . 
 Fracture theory. 
 Diffusion and interpenetrationpolymer chains across the interfacecan also 
result in adhesion.   
 By means of adsorption via Van der Waals dispersion forces and 
hydrogen bonding – Adsorption theory. 
 Wetting theoryappliesto liquid systems which present affinity to the 
surface in order to spread over it. This affinity can be found by using 
measuring techniques such as the contact angle. The general rule states 
that the lower the contact angle, the greater is the affinity 
 Mechanical interlocking theory 
All these numerous theories should be considered as supplementary processes 
involved in the different stages of the mucus/substrate interaction, rather than individual 
and alternative theories. Each and every theory is equally important to describe the 
mucoadhesion process. There is a possibility that there will be initial wetting of the 
mucin, and then diffusion of the polymer into mucin layer, thus causing the fracture in 
the layers to effect the adhesion or electronic transfer or simple adsorption phenomenon 
that finally leads to the perfect mucoadhesion
(5)
. 
1.2.1 Factors Affecting Mucoadhesion(5) 
1.2.1.1 Molecular weight 
The mucoadhesive strength of a polymer increases with molecular weights above 
100,000. 
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1.2.1.2 Flexibility 
It is important that the polymer chains contain a substantial degree of flexibility 
in order to achieve the desired entanglement with the mucus. In general, mobility and 
flexibility of polymers can be related to their viscosities and diffusion coefficients, as 
higher flexibility of a polymer causes greater diffusion into the mucus network. 
1.2.1.3 Cross-linking density 
The average pore size, average molecular weight of the cross-linked polymers, 
and the density of cross-linking are three important, inter-related structural parameters 
of a polymer network. Therefore, with increasing density of cross-linking, diffusion of 
water into the polymer network occurs at a lower rate which, in turn, causes an 
insufficient swelling of the polymer and a decreased rate of interpenetration between 
polymer and mucin. 
1.2.1.4 Hydrogen bonding capacity 
Bioadhesive polymers must have functional groups that are able to form 
hydrogen bonds, and flexibility of the polymer is important to improve this hydrogen 
bonding potential. 
1.2.1.5 Hydration 
Hydration is required for a mucoadhesive polymer to expand and create a proper 
macromolecular mesh of sufficient size, and also to induce mobility in the polymer 
chains in order to enhance the interpenetration process between polymer and mucin. 
However, a critical degree of hydration of the mucoadhesive polymer exists where 
optimum swelling and mucoadhesion occurs. 
1.2.1.6 Charge 
Nonionic polymers appear to undergo a smaller degree of adhesion compared to 
anionic polymers. Strong anionic charge on the polymer is one of the required 
characteristics for mucoadhesion. Some cationic polymers are likely to demonstrate 
superior mucoadhesive properties, especially in a neutral or slightly alkaline medium. 
Additionally, some cationic high–molecular-weight polymers, such as chitosan, have 
shown to possess good adhesive properties.The pH of the membrane affects the 
mucoadhesion as it can influence the ionized or un-ionized forms of the polymers. 
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1.2.1.7 Concentration 
If the concentration of the polymer is too low, the number of penetrating 
polymer chains per unit volume of the mucus is small and the interaction between 
polymer and mucus is unstable. In general, the more concentrated polymer would result 
in a longer penetrating chain length and better adhesion. However, for each polymer, 
there is a critical concentration, above which the polymer produces an “unperturbed” 
state due to a significantly coiled structure. As a result, the accessibility of the solvent to 
the polymer decreases, and chain penetration of the polymer is drastically reduced. 
Therefore, higher concentrations of polymers do not necessarily improve and, in some 
cases, actually diminish mucoadhesive properties. 
1.2.2 Mucoadhesion sites in the body 
The various sites available for mucoadhesion in the body are : 
 Ocular 
 Oral – GIT 
 Buccal 
 Nasal 
 Rectal 
 Vaginal 
Each site of mucoadhesion has its own advantages and disadvantages along with 
the basic property of prolonged residence of dosage form at that particular site. In buccal 
and sublingual sites, there is an advantage of fast onset along with bypassing the first-
pass metabolism, but these sites suffer from inconvenience because of taste and intake 
of food. In GIT, there is a chance for improved amount of absorption because of 
microvilli, but it has a drawback of acid instability and first-pass effects. Rectal and 
vaginal sites are the best ones for the local action of the drug but they suffer from 
inconvenience of administration. Nasal and ophthalmic routes have another drawback of 
mucociliary drainage and clearance by tears, respectively, that would clear the dosage 
form from the site. 
1.3 Oral Mucosa 
The buccal cavity is lined with mucous membrane, which is composed of 
stratified squamous epithelium with small mucus secreting glands
(6)
. The mucus is a 
thick secretion composed of water, electrolytes and several glycoproteins (large 
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polysaccharides bound to smaller quantities of proteins). It is adhesive in nature and 
helps protect the mucosa by binding with the food or other foreign particles and prevents 
their actual contact with the mucosa. The glycol proteins are amphoteric in nature and 
hence can act as a buffer for small amounts of acids and alkali. Mucus also contains 
bicarbonate ions which can neutralize acids
(7)
. 
The mucosa of the buccal cavity is a convenient and easily accessible site for the 
delivery of therapeutic agents for both local and systemic delivery as retentive dosage 
forms, because it has expanse of smooth muscle which is relatively immobile, abundant 
vascularization, rapid recovery time after exposure to stress and the near absence of 
Langerhans cells. Systemic drug delivery via the internal jugular vein bypasses drugs 
from the hepatic first pass metabolism leading to high bioavailability
(8)
. The principle 
uses of these formulations in local drug delivery within the oral cavity are for treating 
oro-dental problems and trigeminal neuralgia.     
 
 
 
.  
Figure 1.1: Structure of the oral mucosa
(9)
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1.4 Buccoadhesive Dosage Forms 
The buccoadhesive dosage forms along with sub-lingual tablets, oral gels and 
ointments, lozenges, rapidly dissolving tablets and chewing gums are the formulations 
targeting drug delivery in the oral cavity
(10)
.Other minor categories includes: drug 
drenched-cotton swab held it in place, either between the teeth or the cheek and gums; 
and a small sac containing the drug/drug formulation placed in the vestibule region near 
the molars. 
 
1.4.1 The different strategies to formulate a buccoadhesive dosage forms are (4): 
a) Matrix-type delivery device: the simplest kind of delivery systems 
where drug is uniformly dispersed into the polymeric matrix; 
b) Dosage form with an impermeable backing layer for 
unidirectional release of drugs;  
c) Dosage form characterized by two layers from which drugs could 
be delivered at different release rate (fast and controlled release); 
and  
d) A mucoadhesive dosage form with an impermeable backing layer, 
a polymeric matrix where drug is dispersed or dissolved and a 
mucoadhesive layer.  
 
 
1.4.2 The different types of bioadhesive dosage forms that are designed for delivery of the 
drug in the buccal cavity are: 
 Bioadhesive Gels 
 Buccal Tablets 
 Bioadhesive Solutions (Oral rinse and Sprays)(9) 
 Buccal Patches and Strips(11) 
 Buccoadhesive Discs 
 Bio-adhesive Microspheres(9) 
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1.5 Buccal Tablets 
 The buccal tablets are formulated similar to the oral tablets but with the inclusion 
of a muco-adhesive polymer either of natural origin (Tragacanth, Guar gum etc...) or 
synthetic and semi-synthetic polymers (CarboxyMethyl Cellulose, Poly Ethylene 
Glycol, Polycarbophils, Hydroxyl Propyl Methyl cellulose, Poloxamer,Poly- Acrylic 
Acid- Hydroxyl Propyl Methylcellulose etc…)These polymers when incorporated in a 
formulation offer varying degrees of muco-adhesion and retention time. 
 Flat, elliptical or capsule-shaped tablets are usually selected for buccal tablets, 
since they can be most easily held between the gum and cheek. The parotid duct empties 
into the mouth at a point opposite the crown of the second upper molar, near the spot 
where buccal tablets are usually placed. This location provides the medium to dissolve 
the tablet and to provide for release of the medication
(12)
. 
 The drugs, usually, presented as candidates for buccal tablets are hormones for 
hormonal replacement therapy, Nicotine for smoking cessation, anti-microbials for the 
treatment of oral infections and anti-emetics. These are all drug candidates for extended 
release formulations
(12)
.  
1.5.1 Types of buccal tablets 
The different types of buccal tablets that can be fabricated are: 
a) A simple mono-lithic matrix tablet 
b) Matrix tablet with  a water impermeable coating – unidirectional drug release 
c) Matrix tablet with a backing membrane – unidirectional release 
d) A bi-layered tablet with a non-adhesive drug reservoir and a mucoadhesive 
polymer layer 
e) A bi-layered tablet with a non-bioadhesive inert layer and a drug containing 
bioadhesive layer. 
f) A triple layered tablet- central drug containing core, upper backing membrane 
and a lower bioadhesive layer. 
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Figure 1.2: Schematic representation of different matrix tablets for buccal delivery
(13)
.  
(Arrows indicate the direction of drug release.) 
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The advantage of the buccal tablets over the other dosage forms is that: 
 The large scale commercial preparation of these is relatively simple and 
economical. (compared to disc, strip and patch technology) 
 They can carry a larger payload of drug.(Compared to strip or patch technology) 
 Duration of drug release can be sustained longer than in the other dosage forms.  
 They are convenient to use and carry around.(Compared to gel technology) 
The buccal tablets are not without their share of short comings: 
 Bulky when compared to the other dosage forms. 
 Can be a source of discomfort to the patient. (Compared to disc or strip) 
 Chances of dislodging from the site of application are relatively higher. 
1.5.2 Marketed Buccal Tablets: 
Table 1.1: Marketed buccal tablets 
Drug  Brand Category 
Miconazole Oravig Tab 
Anti-Fungal 
agent 
Fentanyl Fentora Tab 
Opioid 
Analgesic 
Prochlorperazine 
maleate 
Buccastem M 
Tab 
D2-Antagonist 
1.6 Optimization 
 In order to design the best formulation it is possible to use a trial and error 
approach, but nonetheless it is an inefficient way. Hence, systematic optimization 
techniques are preferable. Optimization refers to the art and science of allocating 
available resources to the best possible effect. Optimization techniques are used in 
industrial planning, allocation, scheduling, decision making etc. These methods can be 
divided into sequential methods, simultaneous methods or a combination of the two. 
1.7 Optimization techniques in pharmaceutical industry(14) 
The pharmaceutical industry initially used random search method (a random 
formulation to get a general idea of the formulation) and evolutionary technique, which 
involves modification of a single parameter by a predefined factor each time, until an 
optimum response is obtained. These methods are time consuming and costly. The 
optimization techniques adopted in the pharmaceutical industry are, simplex method,  
factorial experimental design method, and global optimization techniques. 
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1.7.1 Simplex method 
The method involves identification of the key parameters or variables and 
designing the experiment such that the number of initial trial involved are n+1 (n- 
number of independent variables). The simplex thus formed from the initial data is used 
to optimize the process by moving in the direction of the desired response. This is a 
method of simultaneous or continuous optimization technique 
1.7.2 Factorial design 
The number of experiments required for this study depends upon the number of 
independent variables involved and the different levels at which they are studied, x
n
, 
where, x- number of levels and n- number of independent variables. The results 
expressed as liner equations or interactive equations or quadratic models are fitted by 
carrying out multiple regression analysis and F-statistic to find statistically significant 
terms. This is sequential type of optimization where the experiments are completed prior 
to optimization work. 
1.7.3 Global optimization 
 This method is based on the factorial method. It is better than the previous 
method in that it is used to find the global maxima or minima, whereas the factorial 
design can determine just the local maxima or minima. Hence this method requires 
powerful software tools for computing the complex equations generated.  
1.8 Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)(15) 
 The NSAIDs, sometimes called the aspirin-like drugs, are among the most 
widely used of all drugs. There are now more than 50 different NSAIDs on the global 
market. They provide symptomatic relief from pain and swelling in chronic joint disease 
such as occurs in osteo- and rheumatoid arthritis, and in more acute inflammatory 
conditions such as sports injuries, fractures, sprains and other soft tissue injuries. They 
also provide relief from postoperative, dental and menstrual pain, and from the pain of 
headaches and migraine. As several NSAIDs are available over the counter, they are 
often taken without prescription for other types of minor aches and pains. There are 
many different formulations available, including tablets, injections and gels. Virtually all 
NSAIDs, particularly the 'classic' NSAIDs, can have significant unwanted effects, 
especially in the elderly. Newer agents have fewer adverse actions. 
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1.8.1 Drug interaction: NSAIDs and Antihypertensive agents 
Hypertensive patients use NSAIDs for a variety of indications. NSAIDs inhibit 
prostaglandin-mediated vasodilation and promote salt and water retention. Both of these 
mechanisms may contribute to NSAIDs partially reversing the effects of hypotensive 
drugs, particularly those agents whose mechanism depends on modulating 
prostaglandins, renin, or sodium and water balance. The dose and duration of NSAID 
therapy will partially determine the extent of hypotensive therapy reversal. Higher doses 
of NSAIDs and chronic therapy extending beyond a week will be more likely to increase 
BP. 
This hypertensive effect of NSAIDs is a dose related problem of all classes of 
NSAIDs. Hence the patients on antihypertensive drugs treatment must be monitored 
when prescribed an NSAID concomitantly. 
Hence, thereisan undeniable need for new, lower dosage NSAID formulations, 
with minimal/no-risk of adverse effect, that maintain efficacy comparable with that of 
commercially available dosages and that have a rapid onset of action.
(16)
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2 Literature Review 
Sara Movassaghian et al.,
(17)
 (2013) theorized that Amitriptyline, a tricyclic 
antidepressant that provides local anesthesia by blocking sodium channels, can replace 
topical anesthetics are widely used in dentistry.  They formulated the drug as a intraoral 
mucoadhesive tablets assessed its efficacy in mitigating pain performing a randomized, 
double-blind, placebo-controlled, clinical trial on 25 healthy female volunteers. The 
mucoadhesive tablet was randomly placed for 15 minutes on the buccal mucogingival 
tissue adjacent to the root of the upper lateral incisor, and a placebo was placed on the 
other side. A 27-gauge needle was inserted to touch the alveolar periosteum of the 
designated site. The pain intensity associated with the stimulation was evaluated every 5 
minutes after removing the mucoadhesive tablet using a visual analog pain scale and 
pain rating scoring methods. The study results concluded that the intraoral 
mucoadhesive Amitriptyline tablet is a promising anesthetic device for manipulating 
pain in dental procedures. 
Anthony A. Bavry et al.,
(18)
 (2011) studied chronic and non-chronic NSAIDs users 
among hypertensive patients. The adverse events that they monitored were all-cause 
death, nonfatal myocardial infarction, or nonfatal stroke. The conclusion they arrived at 
was that among the hypertensive patients with coronary artery disease, chronic self-
reported use of NSAIDs was associated with an increased risk of adverse events during 
long term follow-up. 
SuchadaPiriyaprasarth et al.,
(19)
 (2011) investigated the effect of source variation in 
HPMC on the release of drug from HPMC matrix. They used a full factorial 
experimental design to study the in vitro release. The independent variables considered 
were the properties of HPMC from three different sources, the manufacturing process 
and also the drug’s physiochemical properties. This study has shown that HPMC having 
low viscosity resulted in an increased drug release, esp. in the case of poorly soluble 
drugs. 
GoswamiDhrubaSankar et al.,
(20)
(2011)formulated a mucoadhesive tablet of 
Famotidine using various combinations of synthetic (HPMC-K4M, SCMC and Sodium 
alginate) and natural (Tragacanth and Acacia) hydrophilic polymers. The study revealed 
that the formulation containing HPMC K4M and its combination with Tragacanth 
possessed the greatest mucoadhesive strength. 
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Francesco Cilurzo et al.,
(21)
 (2010) formulated a new mucoadhesive prolonged release 
tablet containing Clobetasol-17 propionate for the management of oral lichen planus. 
The tablets were fabricated from poly(Sodium methacrylate, Methylmethacrylate), with 
Hydroxyl Propyl Methyl Cellulose and MgCl2. This formulation when compared to 
placebo and a marketed formulation, mixed extemporaneously with Orobase, resolved 
pain and ulceration to a significantly greater degree. The mucoadhesive tablet was better 
tolerated compared to the taste alteration found in the ointment formulation. Thus the 
effectiveness of a mucoadhesive tablet formulation of Clobetasol-17 propionate over a 
conventional formulation had been established. 
Belgamwar V et al.,
(22)
(2009) prepared mucoadhesive multiparticulate system for oral 
drug delivery using ionic gelation technique. The authors prepared microspheres 
composed of various mucoadhesive polymers including HPMC of various grades like 
K4M, K15M, K100M, E50LV, Carbopol of grades 971P, 974P and Polycarbophil and 
evaluated their mucoadhesive strength. It was observed that HPMC had greater 
mucoadhesive properties than Carbopol and Polycarbophil. 
Ethem I. Akural et al.,
(23)
 (2009) compared the efficacy and tolerance of combination 
of Acetaminophen and Ketoprofen with either drug alone in treating postoperative pain 
(surgical removal of impacted third molar). Single oral doses of Ketoprofen 100 mg + 
Acetaminophen 1000 mg, Ketoprofen 100 mg, Acetaminophen 1000 mg, or placebo 
tablets were administered to these patients and effectiveness was assessed by the onset 
of analgesia, pain intensity difference (PID) from baseline, sum of PID (SPID), and 
duration of analgesic effect. Patients were asked to rate pain intensity on the numerical 
scale rating (NRS) at rest and on dry swallowing. The authors measured onset of pain 
relief using time to PID in ≥1 category at rest or on dry swallowing (PID ≥1). The 
patients were also instructed to record the occurrence of adverse events and the 
supplemental consumption of rescue medication (Ibuprofen). The results from this study 
suggest that the combination of Ketoprofen 100 mg + Acetaminophen 1000 mg 
provided a significantly more rapid onset of analgesia than either drug given alone in the 
management of pain after oral surgery in this patient population. Hence, it is not 
possible to substitute a low dose oral Ketoprofen tablet to achieve effective pain relief. 
 
  
14 
 
SolimanMohammadi-Samani et al.,
(24)
(2005) in their research, studied the effect of 
mucoadhesive polymers such as Hydroxyl Propyl Methyl Cellulose (HPMC) with 
viscosity grade 60 and 500 mPas, Sodium Carboxy Methyl Cellulose (NaCMC) and 
Carbopol 934 (Cp 934) alone or in combination with each other on the release profile of 
Prednisolone was studied and mucoadhesion strength of these buccoadhesive 
formulations was evaluated. The results showed that with different blends of HPMC 
viscosity grade 500 mPas or NaCMC and Cp 934 with increasing in HPMC or 
NaCMC/Cp 934 ratio a remarkable decrease in the rate of drug release and an 
appreciable increase in the mucoadhesion strength was observed. Except from the 
formulations prepared with HPMC viscosity grade 60 and 500 mPas, other formulation 
hadmore fluctuations in release profiles and their kinetics of release were not fitted to 
zero order model. 
 
C. Narendra et al.,
(25)
 (2005) evaluated the effect of formulation variables on release 
properties and bioadhesive strength in development of three layered buccal compact 
containing highly water-soluble drug Metoprolol Tartrate by statistical optimization 
technique.The three layered buccal compact comprises of a peripheral layer, a core layer 
and a backing layer. The peripheral polymer ratio (Carbopol 934P: HPMC 4KM) and 
core polymer ratio (HPMC 4KM: Na alginate) as two independent formulation 
variables. Four dependent variables were considered: bioadhesionforce, percentage drug 
release at 8h, T50% and release exponent (n). The release profile data was subjected to 
curve fitting analysis for describing the release mechanism of MetoprololTartarate from 
three layered buccal compact. The main effects and interaction terms was quantitatively 
evaluated by quadratic model. The decrease in Metaprolol Tartrate release was observed 
with an increase in both the formulation variables and as the Carbopol:HPMC ratio 
increases the bioadhesive strength also increased. The desirability function was used to 
optimize the response variables and the observed responses were in agreement with the 
experimental values, they stated.  
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M.L. Vueba et al.,
(26)
 (2004) studied the effects of polymer substitution and type of 
diluent on Ketoprofen release mechanism. The polymers studied were Methyl Cellulose, 
HPC and HPMC and the diluents taken were lactose monohydrate and β-cyclodextrin. 
The study concluded that HPMC was the one suited for designing modified release 
formulations of Ketoprofen and the choice of diluent used in the formulation affects its 
release pattern.   
JafarAkbari et al.,
(27)
 (2004) studied the effect of lactose (a soluble excipient) and di-
Calcium phosphate(insoluble excipient) on dissolution rate, kinetic of release and 
adhesion force of buccal-adhesive tablets of Propranolol HCl. Each tablet composed of 
80 mg Propranolol HCl, 80 mg HPMC K4M and Polycarbophil AA1 and lactose or 
DCP with different ratios. The results showed that the presence of the fillers increased 
dissolution rate of the drug and reduced the bioadhesion force. The release mechanisms 
from HPMC K4M were found to be diffusion and erosion. 
LuanaPerioli et al.,
(28)
 (2004) prepared mucoadhesive tablets using different mixture of 
Cellulose and Polyacrylic derivatives to obtain new formulations containing 
Metronidazole for periodontal disease treatment. The tablet formulations were analyzed 
for their swelling studies, ex vivo and in vivo mucoadhesive time, ex vivo mucoadhesion 
force, in vitro and in vivo release. The best mucoadhesive performance and the best in 
vitro drug release profile were achieved by using HydroxyEthyl Cellulose (HEC) and 
Carbomer 940 2:2 ratio. The chosen tablet, containing 20 mg of Metronidazole, 
performed 12 h drug sustained release with buccal concentrations always higher than its 
MIC. This study shows that a buccal tablet formulation is a feasible method of treating 
diseases of the oral cavity. 
Mario Jug et al.,
(29)
 (2004) investigated the effect of drug-cyclodextrin complexation on 
the buccoadhesive controlled release tablets made up of HPMC-Carbopol matrix. The 
drug employed was Piroxicam which is only sparingly water soluble. The complexation 
with Hydroxypropyl-β-Cyclodextrin resulted in higher solubility due to the higher water 
uptake by the polymer. The complex also increased the diffusivity of the drug through 
the membrane (in vitro). The inclusion of hydrophilic polymers can increase the drug 
solubility and its permeation. 
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H.YeşimKarasulu et al.,(30) (2004) developed a more effective treatment for vaginal 
candidasis, by formulating ketoconazole in a bioadhesive tablet formulations that 
increased the time of contact of drug with the vaginal mucosa. The bioadhesive vaginal 
tablets were prepared by direct compression of sodium Carboxy Methyl Cellulose or 
Poly Vinyl Pyrrolidone or Hydroxy Propyl Methyl cellulose (HPMC E50) with 
Ketoconazole. The dissolution studies of bioadhesive tablets and commercial ovules 
were carried out and a good sustained release action was obtained with bioadhesive 
tablets containing 1:1 and 1:2 drug/polymer ratio using HPMC E50. These bioadhesive 
tablets containing 400 mg of KTZ showed a zero-order drug release kinetic. 
Donald R. Mehlisch
(31)
(2002)presented his review on post-operative dental pain 
management. He stated that an experience of poorly managed pain related to dental 
treatment can lead patients to avoid or postpone treatment. NSAIDs have been the 
traditional treatment for moderate pain and inflammation. NSAIDs such as Ibuprofen, 
Ketorolac, Flurbiprofen, Ketoprofen, Diclofenac, Aspirin and Aspirin derivatives 
diminish postoperative hyperalgesia peripherally. He concludes that the use of 
combinations of NSAIDs and or centrally acting analgesics is a better approach 
compared to the use of a single agent, which gives rise to adverse reactions. 
DesiderioPassàli et al.,
(32)
(2001)compared the efficacy and tolerability of mouthwash 
formulations of Ketoprofen lysine salt, an anti-inflammatory agent, and Benzydamine 
hydrochloride, a local anesthetic, in patients with acute inflammation of the pharyngeal 
cavity. It was observed that Ketoprofen lysine salt mouthwash exerts a significantly 
longer first-application analgesic action with significantly greater local tolerability than 
Benzydamine hydrochloride in patients with pharyngeal pain of inflammatory and/or 
infectious origin. 
RadkoKomers et al.,
(33)
 (2001) investigated the risk of congestive heart failure 
associated with combined use of diuretics and NSAIDs in patients older than 55years. 
The use of NSAIDs concomitantly with diuretics is known to exacerbate the existing 
CHF condition in the patients. The study concluded that the simultaneous use of the 
above two classes of drugs increased the risk of hospitalization for CHF by as much as 
2-fold, especially in those with an existing serious CHF. 
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Gary E. Ruoff
(34)
(1998) has reviewed that an estimated 25% of the overall population 
of the United States and 55% to 60% of the population aged 65 to 74 years are 
hypertensive. Many patients with hypertension also take NSAIDs, the most commonly 
prescribed analgesic medications in the United States. It is estimated that as many as 20 
million patients and 12% of the population aged ≥60 years are taking concurrent 
NSAIDs and antihypertensive medication. This overlap is significant, because NSAIDs 
inhibit eicosanoid synthesis and can thus limit the effectiveness of antihypertensive 
drugs that exert all or part of their blood pressure—lowering action through the 
stimulation of eicosanoid synthesis or release. Overviews of clinical trial data indicate 
that the blood pressure of patients with controlled hypertension can be raised by 3 to 6 
mm Hg during concurrent treatment with NSAIDs, which can produce a significant 
increase in subsequent stroke, end-stage renal disease, or congestive heart failure. Since, 
the incidence of these adverse events increases age, the use of NSAIDs in the elderly 
and the risk category patients must be monitored or else alternative drugs such as 
Tramadol or Acetaminophen must be used. 
P Minghetti et al.,
(35)
 (1998) experimented on buccoadhesive formulations of Acitretin, 
an aromatic retinoid used in the treatment of buccal keratinization disorders.Ten 
different formulations of two-layer buccoadhesive tablets were considered. They 
formulated ten different formulations of two-layer buccoadhesive tablets where 
Carbopol 934P:HPMC K4M, 1:2 ratio, formed the lower buccoadhesive layer and 
HPMC matrix (different grades) formed the rate controlling polymer in the upper layer. 
Lactose was used as the diluent. The authors observed that a high concentration of 
HPMC (viscosity grade E5) produced a prolonged drug release compared to that of a 
low concentration formulation.  
Rajesh Khanna et al.,
(36)
 (1996) formulated buccoadhesive erodible tablets for local 
delivery of Clotrimazole to the oral cavity using different bio-adhesive polymers along 
with soluble excipients like mannitol and Poly Ethylene Glycol-6000. The in vitro 
adhesion time and release characteristics were found to be a function of the type of 
polymer and also the total composition of the tablets. The study revealed that the 
bioadhesive polymers in conjugation with the other excipients dictated the adhesive 
property and release property of the tablets  
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BuketTaylan et al.,(37)(1996) experimented with sustained release cum buccoadhesive 
tablet formulation using HPMC and Polycarbophil. The release from a single dose 
HPMC matrix as compared to a conventional dosage form revealed a smoother plasma 
drug profile for the former. Thus HPMC is suitable for the sustained release of the drug 
from the tablet although the API used, Propranolol caused oral ulcers.  
A.P. Sam et al.,(38)(1992) evaluated the mucoadhesive property of various film forming 
and non-film forming polymers using Wilhelmy plate method. The experimental results 
showed that the mucoadhesive property of the polymers are in the following ranking : 
CMC > HPMC K100M > HPMCP > Polycarbophil> HPMC K4M > Amylopectin > 
Eudragit RS 100. The strength of mucoadhesion also depended on the surface area of the 
polymer submerged in the mucus. 
P. Giunchedi et al.,
(39)
 (1991) designed a pulsatile dosage form of Ketoprofen using 
tablet in capsule technique. Their rationale was that diseases like rheumatoid disorders 
are influenced by circadian rhythms. Hence, a mere extended release dosage form would 
not be an optimum choice, they concluded. The drug was formulated as a ‘multiple-unit’ 
dosage form, consisting of four hydrophilic matrices made of HPMC, placed in a hard 
gelatin capsule. The study results showed that the dosage form had a pulsatile profile as 
evidenced from the spike in the plasma drug concentration after the 2
nd
 and 8
th
 hour of 
administration. Thus an existing drug can serve better when formulated appropriately. 
 
D.A. Henry
(40)
(1988) reviewed that the adverse reaction to NSAIDs based on their 
pharmacological actions. NSAIDs precipitate renal syndromes, of which functional renal 
impairment is the most important. This may precipitate cardiac failure, and 
hyperkalaemia is an additional hazard. Antagonism of the action of diuretics may 
contribute to the fluid retention, and antagonism of antihypertensive therapy is probably 
quite common and may result in additional unnecessary therapy. He proposed that 
patients at risk of functional renal impairment from NSAIDs can be identified readily 
and in these subjects the drugs have to be used with great care and with appropriate 
monitoring. 
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A.G. Eshra et al.,
(41)
 (1988) studied the influence of milk and of a standard breakfast on 
Ketoprofen bioavailability from commercial capsules (50 mg). The drug was 
administered as a single oral dose. They evaluated the absorption rate by means of 
urinary excretion measurements and the drug urine concentrations were determined by 
HPLC. The data were then statistically analyzed by the t-test for paired observations. It 
was found that milk significantly reduced the extent of Ketoprofen absorption, while 
both the rate and extent of absorption were significantly reduced by food. This shows 
that the justification of taking NSAIDs along with food to reduce their gastric tract 
injury can lead to reduced bio-availability and delayed onset of action. 
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3 Aim and Objectives 
The aim of the present investigation was to formulate Ketoprofen buccal tablets 
containing 12.5mg, with a thickness of about 2mm and a diameter less than 4mm. 
Ketoprofen is a Non- Steroidal Anti-Inflammatory Drug, prescribed for the treatment of 
rheumatoid arthritis, osteo-arthritis and dental pain & inflammation. In general, 
Ketoprofen falls under BCS – class II (low solubility / high permeability), but pH 
dependent solubility behavior of Ketoprofen is used as the concept of designing buccal 
dosage form in present investigation, since the dose number of Ketoprofen is 0.00529.  
Therefore the objective of the formulation includes:      
Preparation of various formulations of Ketoprofen buccal tablets, using various 
grade of HPMC (K4M, K100 and E50) and different granulation technique for the 
manufacturing process, based on a 2
4
-full Factorial design was the primary objective. 
Determination of the in vitro drug release profile and swelling index of the Ketoprofen 
buccal tablets was also included in the study. The buccoadhesive property and the ex 
vivo drug permeation for the various formulations are to be evaluated. Compiling the 
data in an optimization-software and analyzing the effect of different independent 
variables on the various responses is also the part of the investigation. The performance 
of evaluations, on the finished product dosage form of Ketoprofen buccal tablets, like 
weight variation, friability, hardness, and thickness, are to be included in the study. In 
order to determine the drug release kinetics, the ex vivo drug release data is to be fitted 
into the various kinetic models.  
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4 Plan of Work 
The present study focused on the formulation of buccal tablets of Ketoprofen for 
use in mitigating pain and inflammation in the oral cavity. 
4.1 Flow of work 
 
Figure 4.1: Schematics of plan of work 
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5 Drug and Excipient Profile 
5.1 Ketoprofen(42) 
5.1.1 Official 
USP, BP, IP 
5.1.2 Chemical name and CAS number 
2-(3-benzoylphenyl)-propionic acid; 89796-99-6 
5.1.3 Molecular formula and molecular weight 
C16H14O3; 254.29 
5.1.4 Melting point  
≈95°C   
5.1.5 Origin of substance  
Synthetic 
5.1.6 Structure 
 
5.1.7 Category 
Non-Steroidal Anti-Inflammatory Drug 
5.1.8 Solubility  
It is freely soluble in ethanol, chloroform, acetone, ether; soluble ib benzene and 
strong alkali but practically insoluble in water @ 20°C, 
5.1.9 Proprietary names 
Actron, Nexcede, Orudis, Orudis KT, Oruvail, Apo-Keto 
5.1.10 Clinical Pharmacology 
It is a racemate with only the S-enantiomer possessing activity. 
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5.1.11 Mechanism of action 
It inhibits the prostaglandin and leukotriene synthesis 
It has an antibradykinin activity as well as lysosomal membrane stabilizing 
action 
5.1.12 Pharmacokinetics 
 Absorption 
Ketoprofen is rapidly and well absorbed after oral administration. Peak plasma 
concentrations are reached approximately 0.5-2 hours after an oral dose. The presence of 
food slows the absorption. 
 Distribution 
Aceclofenac is highly protein bound (>99%). The volume of distribution is 
approximately 0.1L/kg. 
 Metabolism 
Ketoprofen is metabolized by way of conjugation to the glucuronic acid. But since the 
metabolite is unstable it reverts back to the parent compound. Thus the conjugate serves 
as a reservoir for the drug. There are no known active metabolite for Ketoprofen 
 Excretion 
Renal excretion is the main route of elimination, with ~80% of the administered dose 
excreted within 24h of administration. The plasma elimination half-life of the drug is 
approximately 2.05±0.58 h. 
5.1.13 Indications 
Ketoprofen is indicated in Rheumatoid arthritis and osteo-arthritis, 
dysmenorrhea, and post-operative pain. 
5.1.14 Doseage 
50-75mg every 4 hours 
5.1.15 Contraindications 
Ketoprofen should not be administered to patients hypersensitive to Ketoprofen 
or other NSAID’s, or patients with history of Aspirin or NSAID’s related allergic and to 
patients with anaphylactic reactions or with peptic ulcers or GI bleeding, moderate or 
severe renal or hepatic impairment. 
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5.1.16 Adverse effects 
The most common side effects are rash, ringing in the ears, headache, dizziness, 
drowsiness, abdominal pain, nausea, diarrhea, constipation, heartburn, retention of fluid, 
and shortness of breath. Serious side effects are rare and mostly result from 
gastrointestinal (GI) damage. 
5.1.17 Drug interactions 
Drug interactions associated with Ketoprofen are similar to those observed with 
other NSAID’s. It interacts with the anti-hypertensive drugs other than Calcium channel 
blockers by reducing their efficacy. 
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5.2 Excipient Profile 
5.2.1 Hypromellose(43) 
5.2.1.1 Nonproprietary names 
BP: Hypromellose;   USP: Hypromellose 
JP: Hypromellose;   PhEur: Hypromellose 
5.2.1.2 Synonyms 
Benecel MHPC; E464; hydroxypropyl methylcellulose; HPMC; hypromellosum; 
Methocel; methylcellulose propylene glycol ether; methyl hydroxypropylcellulose; 
Metolose; MHPC; Pharmacoat; Tylopur; Tylose MO. 
5.2.1.3 Chemical name and CAS Registry Number 
Cellulose hydroxypropyl methyl ether  [9004-65-3] 
5.2.1.4 Chemical Structure 
where R is 
H, CH3, or CH3CH(OH)CH2 
 
 
5.2.1.5 Applications in Pharmaceutical Formulation 
Hypromellose is widely used in oral, ophthalmic and topical pharmaceutical 
formulations. 
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Table 4.1: Application of HPMC at various concentrations 
Dosage Form Concentration Application 
 
 
Tablets 
  
  
2-5% w/w Binder 
10-80% w/w 
(High 
Viscosity 
grades) 
Matrix- XR 
Formulations 
2-20% w/w Film Coating 
Liquids 0.25-5.0% w/w 
Suspending/Thickening 
Agents 
 
In addition, it is used as bioadhesive or mucoadhesive material in various types of 
formulations. In topical formulations,  as an emulsifying, suspending and stabilizing 
agent. 
5.2.1.6 Properties of Hypermellose 
Table 4.2: Properties of HPMC 
Acidity/alkalinity 
pH 5.0–8.0 for a 2% w/w aq. 
Solution 
Ash ≤1.5% 
Auto-ignition 
Temperature 
360°C 
Density 
0.341 g/cm
3
, Bulk 
0.557 g/cm
3
, Tapped 
1.326 g/cm
3
, True 
Melting Point 
190–200°C. 
 (Browns)  
225–230°C. 
(chars) 
170–180°C. 
(Glass Transition Temperature) 
Moisture Content 
Hygroscopic-Depends on the relative 
humidity of the surrounding 
Specific Gravity 1.26 
Solubility 
Soluble in cold water.   Insoluble in 
hot-water, ethanol, ether 
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5.2.1.7 Grades of Hypermellose 
Table 4.3: HPMC viscosity grades 
Hypromellose Products 
Pharmacopoeial 
Designation 
Viscosity @ 
2%w/v Aq. 
Solution (mPas) 
Methocel K100 2208 100 
Methocel K4M 2208 4000 
Methocel E50 2910 50 
5.2.1.8 Stability and Storage Conditions 
Solutions are stable at pH 3–11. It is temperature sensitive, gelation occurs at 50 
- 90
o
C Aqueous solutions are liable to microbial spoilage and should be preserved with 
an antimicrobial preservative. Hypromellose powder should be stored in a well-closed 
container, in a cool, dry place. 
5.2.1.9 Incompatibilities 
Hypromellose is incompatible with some oxidizing agents. 
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5.2.2 Microcrystalline Cellulose(43) 
5.2.2.1 Nonproprietary Names 
BP: Microcrystalline cellulose;   JP: Microcrystalline cellulose 
PhEur: Cellulosummicrocristallinum;  USP-NF: Microcrystalline cellulose 
5.2.2.2 Synonyms 
Avicel PH, Celex, cellulose gel, Celphere, Ceolus KG, Crystalline Cellulose, E460, 
Emcocel, Ethispheres, Fibrocel, Pharmacel, Tabulose, Vivapur. 
5.2.2.3 Chemical Name and CAS Registry Number 
Cellulose [9004-34-6] 
5.2.2.4 Empirical Formula and Molecular Weight 
(C6H10O5)n ;       Mol. Wt. ≈36 000 
where n ≈ 220. 
5.2.2.5 Structural Formula 
 
 
 
 
5.2.2.6 Functional Category 
Adsorbent, Suspending agent, Tablet and Capsule diluent, Tablet disintegrant. 
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5.2.2.7 Applications in Pharmaceutical Formulation 
It is used as a binder/diluent in oral tablet and capsule formulation in both wet-
granulation and direct-compression processes. It also has some lubricant(8) and 
disintegrant properties that make it useful in tableting 
 
Table 4.4: Applications of MCC at different concentrations 
Use 
Concentration 
(%) 
Adsorbent 20–90 
Anti-adherent 5–20 
Capsule 
binder/diluent 
20–90 
Tablet 
disintegrant 
5–15 
Tablet 
binder/diluent 
20–90 
 
5.2.2.8 Properties of Avicel PH 112 
Table 4.5: Properties of MCC PH 112 
Grade 
Nominal Mean 
Particle 
Size(µm) 
Particle Size Analysis 
Moisture 
Content (%) 
Mesh Size 
Percentage 
Retained 
Avicel PH-112 
100 60 ≤8 ≤1.5 
5.2.2.9 Stability and Storage Conditions 
Microcrystalline cellulose is a stable though hygroscopic material. The bulk 
material should be stored in a well-closed container in a cool, dry place. 
5.2.2.10 Incompatibilities 
Microcrystalline cellulose is incompatible with strong oxidizing agents. 
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5.2.3 Povidone(43) 
5.2.3.1 Nonproprietary Names 
BP: Povidone;    JP: Povidone 
PhEur: Povidone;   USP: Povidone 
5.2.3.2 Synonyms 
E1201; Kollidon; Plasdone; poly[1-(2-oxo-1-pyrrolidinyl)ethylene]; polyvidone; 
polyvinylpyrrolidone; povidonum; Povipharm; PVP; 1-vinyl-2-pyrrolidinone polymer. 
5.2.3.3 Chemical Name and CAS Registry Number 
1-Ethenyl-2-pyrrolidinone homopolymer [9003-39-8] 
5.2.3.4 Empirical Formula and Molecular Weight 
Povidone K 90 -1 000 000 (approx.) 
5.2.3.5 Chemical Structure 
 
5.2.3.6 Functional Category 
Disintegrant; dissolution enhancer; suspending agent; tablet binder 
5.2.3.7 Applications in Pharmaceutical Formulations 
Table 4.6: Pharmaceutical applications of PVP 
Use Concentration (%) 
Carrier for drugs 10–25 
Dispersing agent Up to 5 
Eye Drops (solubilizer) 2–10 
Suspending agent Up to 5 
Tablet  
(binder, diluent or coating agent) 
0.5–5 
 
 
  
31 
5.2.3.8 Physical Properties 
 
Table 4.7: Physical properties of PVP 
Acidity/alkalinity 
pH= 4.0-7.0  
(5% aq. solution PVP K 90) 
Density 
 0.29–0.39 g/cm3 (bulk) 
0.39–0.54 g/cm3 (tapped) 
1.18 g/cm3 (true) 
Melting point Softens at 150°C. 
Moisture content 
Very hygroscopic. Depends on the 
relative humudity of the environment 
Particle size 
distribution -   PVP 
K90 
 90% >200µm; 95% > 250µm 
Solubility 
Freely soluble in acids, chloroform, 
ethanol (95%), ketones, methanol, 
and water; practically insoluble in 
ether, hydrocarbons, and mineral oil. 
In water, the concentration of a 
solution is limited only by the 
viscosity of the resulting solution, 
which is a function of the K-value 
Viscosity PVP K90 
(5% solution @ 25°C 
Ethanol (95%): 53.0 mPas;     
Propanol: 90.0 mPas 
 
5.2.3.9 Stability and Storage Conditions 
Povidone darkens to some extent on heating at 1508C, with a reduction in 
aqueous solubility. It is stable to a short cycle of heat exposure around 110–1308C; 
steam sterilization of an aqueous solution does not alter its properties. Aqueous solutions 
are susceptible to mold growth and consequently require the addition of suitable 
preservatives. 
Povidone may be stored under ordinary conditions without undergoing 
decomposition or degradation. However, since the powder is hygroscopic, it should be 
stored in an airtight container in a cool, dry place. 
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5.2.3.10 Incompatibilities 
Povidone is generally compatible in solution with a wide range of inorganic 
salts, natural and synthetic resins, and other chemicals. However, it forms molecular 
adducts in solution with sulfathiazole, sodium salicylate, salicylic acid, phenobarbital, 
tannin, and other compounds. 
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5.2.4 Magnesium stearate(43) 
5.2.4.1 Non-proprietary Names 
BP: Magnesium stearate;  JP: Magnesium stearate  
PhEur: Magnesiistearas;  USPNF: Magnesium stearate  
5.2.4.2 Synonyms 
Magnesium octadecanoate,  octadecanoic acid magnesium salt and stearic acid 
magnesium salt.  
5.2.4.3 Chemical Name 
Octadecanoic acid magnesium salt  
5.2.4.4 Empirical Formula and Molecular Weight 
[CH3 (CH2)16COO]2 Mg ; Mol.Wt. = 591.34  
5.2.4.5 Chemical Structure 
 
 
5.2.4.6 Physical Properties 
Melting point - 117-150˚C  
Solubility - It is practically insoluble in ethanol (95%), ether and water; slightly 
soluble in warm benzene and warm ethanol (95%).  
5.2.4.7 Functional Category 
Tablet and capsule lubricant. 
5.2.4.8 Applications in Pharmaceutical Formulations 
It is widely used in cosmetics, foods and pharmaceutical formulations. It is 
primarily used as a lubricant in the manufacturing of tablets and capsules, in the 
concentration of 0.25-5.0%. It is also used in barrier creams.  
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5.2.4.9 Stability and Storage Conditions 
It should be stored in a well closed container in a cool, dry place.  
5.2.4.10 Incompatibilities 
It is incompatible with strong oxidizing agents, strong acids, alkalis and iron 
salts. It cannot be used in products containing aspirin, some vitamins and most 
alkaloidal salts. 
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5.2.5 Isopropyl Alcohol(43) 
5.2.5.1 Nonproprietary Names 
BP: Isopropyl Alcohol;  JP: Isopropanol 
PhEur: Isopropyl Alcohol;  USP: Isopropyl Alcohol 
5.2.5.2 Synonyms 
Alcohol isopropylicus; dimethyl carbinol; IPA; isopropanol; petrohol; 2-propanol; sec-
propyl alcohol; rubbing alcohol. 
5.2.5.3 Chemical Name and CAS Registry Number 
Propan-2-ol [67-63-0] 
5.2.5.4 Empirical Formula and Molecular Weight 
C3H8O;  60.1 
5.2.5.5 Structural Formula 
 
 
 
5.2.5.6 Functional Category 
Disinfectant; solvent. 
5.2.5.7 Applications in Pharmaceutical Formulation 
Isopropyl alcohol is used as a solvent both for tablet film-coating and for tablet 
granulation,where the isopropyl alcohol is subsequently removed by evaporation. Its 
primary use, though, is as a solvent in topical formulations. 
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5.2.5.8 Properties 
 
Table 4.8: Properties of IPA 
Antimicrobial activity 
Isopropyl alcohol is bactericidal 
@ >70% v/v 
Autoignition 
temperature 
425°C 
Boiling point 82.4°C 
Dielectric constant D
20
 18.62 
Flammability Flammable. 
Freezing point -89.5°C 
Melting point -88.5°C 
Moisture content 
0.1–13% w/w for commercial 
grades 
Refractive index n
20
D= 1.3776;  n
20
D= 1.3749 
Solubility 
Miscible with benzene, 
chloroform, ethanol (95%), ether, 
glycerin, and water. Soluble in 
acetone; insoluble in salt solution 
Specific-gravity       0.786 
Vapor density(relative)  2.07 (air = 1) 
Vapor-pressure 
133.3 Pa (1 mmHg) at - 26.1°C; 
4.32 kPa (32.4 mmHg) at 20°C; 
5.33 kPa (40 mmHg) at 23.8°C; 
13.33 kPa (100 mmHg) at 39.5°C. 
Viscosity(dynamic)  2.43 mPas@20°C 
 
5.2.5.9 Stability and Storage Conditions 
Isopropyl alcohol should be stored in an airtight container in a cool, dry place. 
5.2.5.10 Incompatibilities 
Incompatible with oxidizing agents such as hydrogen peroxide and nitric acid, 
which cause decomposition. Isopropyl alcohol may be salted out from aqueous mixtures 
by the addition of sodium chloride, sodium sulfate, and other salts, or by the addition of 
sodium hydroxide. 
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6 Materials and Methodology 
6.1 Materials and Equipments 
6.1.1 Materials 
 
Table 4.9: List of materials and their application in the formulation 
S.no. Materials Manufacturers/Suppliers Application 
1 Ketoprofen IP PharmaFabrikon, India API 
2 
Methocel K4M Dow Wolff Cellulosics, 
Germany 
Buccoadhesive 
Polymer  (HPMC) 
3 
Methocel K100 Dow Wolff Cellulosics, 
Germany 
Buccoadhesive 
Polymer (HPMC) 
4 
Methocel E50 Dow Wolff Cellulosics, 
Germany 
Buccoadhesive 
Polymer (HPMC) 
5 
Plasdone K 90 
ISP Pharmaceuticals, USA Binder 
(PVP) 
6 
Avicel PH 112 
FMC Biopolymer, USA Filler 
(MCC) 
7 
Magnesium 
Stearate 
PharmaFabrikon, India Glidant 
8 
Isopropyl Alcohol 
PharmaFabrikon, India Solvent 
(IPA) 
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6.1.2 Instruments and Equipment 
Table 4.10: List of instruments and equipments   
S.no. Instruments/Equipment Manufacturer 
1 Digital Balance Infra, India  
2 Sieve no. 16 SECOR, India 
3 Sieve no. 20  SECOR, India 
4 Sieve no. 30  SECOR, India 
5 
6 Station Rotary Compression 
Machine 
Accura Punching Machine 
6 Vernier Calipers Gogna, India  
7 Analytical Digital Balance Mettler Toledo, Germany 
8 Hardness Tester 
Dr.SchleunigerPharmatron, 
Switzerland 
9 Friability Tester Electrolab, India 
10 Disintegration Apparatus Electrolab, India 
11 Dissolution Apparatus Electrolab, India 
12 Franz Diffusion Cell Orchid Scientifics, India 
13 Magnetic Stirrer / Heating Unit REMI, India 
14 UV Visible Spectro Photometer Shimadzu, Japan 
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6.2 Methodology 
6.2.1 Design of Experiment 
The important formulation factors identified were the concentrations of: 
 concentration of HPMC K4M,   
 concentration of HPMC K100,  
 concentration of HPMC E50, and  
 the methods of manufacture – wet granulation (non-aqueous) and 
direction compression. 
Taking these as the independent variable, the experiment was designed as a 2-
level full Factorial. (2
n – where, n is the number of independent variables) 
Table 4.11: Levels of Independent Variables 
Independent 
Variables 
Low Level High Level 
% HPMC K4M 5 20 
% HPMC K100 10 40 
% HPMC E50 5 20 
Method of 
Manufacture 
Direct 
Compression 
Wet 
Granulation 
 
Table 4.12: Experimental design based on key parameters 
S.no: 
Factor 1: 
Manufacturing 
Process 
Factor 2: 
% HPMC 
K4M 
Factor 3: 
% HPMC 
K100 
Factor 4: 
% HPMC 
E50 
1 DC 5 10 5 
2 DC 5 10 20 
3 DC 5 40 5 
4 DC 5 40 20 
5 DC 20 10 5 
6 DC 20 10 20 
7 DC 20 40 5 
8 DC 20 40 20 
9 WG 5 10 5 
10 WG 5 10 20 
11 WG 5 40 5 
12 WG 5 40 20 
13 WG 20 10 5 
14 WG 20 10 20 
15 WG 20 40 5 
16 WG 20 40 20 
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6.2.2 Pre-compressional Studies 
Ketoprofen and the polymers provided by the industry were subject to DSC 
analysis. 
Ketoprofen was further assayed by titrimetric analysis
(42)
. Ketoprofen was then subject 
to particle size analysis by sieve method
(42)
 and its solubility in pH 6.8 was determined 
by equilibrium method. 
6.2.3 Formulation of Ketoprofen Buccal Tablets 
The formulations were prepared according to a predefined random order so as to 
nullify the extemporaneous effects such as time, environmental temperature, humidity 
etc…  
6.2.3.1 Formulations prepared by dry granulation method 
 
Table 4.13: Formulations prepared by direct compression method 
MANUFACTURING 
PROCESS 
DIRECT COMPRESSION 
STANDARD 
ORDER 
1 2 3 4 5 6 7 8 
FORMULATION 
CODE 
DC.5.10.5 DC.5.10.20 DC.5.40.5 DC.5.40.20 DC.20.10.5 DC.20.10.20 DC.20.40.5 DC.20.40.20 
KETOPRFEN 12.5 12.5 12.5 12.5 12.5 12.5 12.5 12.5 
HPMC K4M 0.63 0.63 0.63 0.63 2.5 2.5 2.5 2.5 
HPMC K100  1.25 1.25 5 5 1.25 1.25 5 5 
HPMC E50  0.63 2.5 0.63 2.5 0.63 2.5 0.63 2.5 
MG STEARATE 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 
MCC PH 112 51.49 49.62 47.74 45.87 49.62 47.75 45.87 44 
Note: All quantities in milligram 
 The ingredients weighed out for 2000 tablets. 
 Ketoprofen, Magnesium stearate, HPMC K4M, HPMC K100, and HPMC E50 
were then sieved using sieve no. 30. 
 The MCC PH 112 was sieved separately using sieve no. 16.  
 The two were then hand mixed thoroughly.  
 The blended powders were then compacted using a 6 station punching machine 
using 7/32 punch tooling with an average weight of 70 mg per tablet. 
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6.2.3.2 Formulations prepared by wet granulation (non-aqueous) method 
Table 4.14: Formulations prepared by wet granulation method 
MANUFACTURING 
PROCESS 
WET GRANULATION 
STANDARD 
ORDER 
9 10 11 12 13 14 15 16 
FORMULATION 
CODE 
WG.5.10.5 WG.5.10.20 WG.5.40.5 WG.5.40.20 WG.20.10.5 WG.20.10.20 WG.20.40.5 WG.20.40.20 
KETOPRFEN 12.5 12.5 12.5 12.5 12.5 12.5 12.5 12.5 
HPMC K4M 0.63 0.63 0.63 0.63 2.5 2.5 2.5 2.5 
HPMC K100 1.25 1.25 5 5 1.25 1.25 5 5 
HPMC E50 0.63 2.5 0.63 2.5 0.63 2.5 0.63 2.5 
MG STEARATE 3 3 3 3 3 3 3 3 
PVP K 90 2.8 2.8 2.8 2.8 2.8 2.8 2.8 2.8 
MCC PH 112 49.19 47.32 45.44 43.57 47.32 45.45 43.57 41.7 
IPA q.s. q.s. q.s. q.s. q.s. q.s. q.s. q.s. 
Note: All powder quantities in milligram 
 IPA measured in milliliter 
 The ingredients were weighed out for 2000 tablets. 
 All the ingredients except Magnesium stearate, HPMC E50, PVP K90 and IPA 
were sieved and hand mixed together. 
 Then PVP K 90 was dissolved in sufficient quantity of IPA was added slowly in 
small quantities to the previous blend and it was hand mixed thoroughly. 
 The wet mass was air dried to remove the IPA.  
 The dried mass was then passed through sieve no. 30 to obtain granules. 
 To the above obtained granules, HPMC E50 and Magnesium Stearate were 
added and mixed well.  
 The granular mixture was then compacted using a 6 station punching machine 
using 7/32 punch tooling with an average weight of 70 mg per tablet. 
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6.2.4 Ketoprofen – Buccal Tablet Evaluations 
6.2.4.1 Uniformity of Weight 
Twenty tablets were selected at a random and weighed individually. The average 
weight was calculated. The percentage deviation of tablets was calculated and compared 
with the standard specifications. 
Table 4.15: Limits for Tablet Weight Variation 
S.no Average weight of a tablets % Deviation 
1 80 mg or less ±10 
2 80-250 mg ±7.5 
3 More than 250mg ±5 
6.2.4.2 Thickness  
The thickness was measured to determine the uniformity of size and shape. 
Thickness of the Ketoprofen buccal tablets was measured using vernier caliper. 
6.2.4.3 Hardness 
Hardness is defined as the force required for breaking a tablet at diametric 
compression test and it is termed as tablet crushing strength. Hardness of the prepared 
formulations was determined using a tablet hardness tester. It was expressed in kp. 
6.2.4.4 Friability 
Friability of the prepared formulations was determined by using a friability 
tester. Pre- weighed sample of tablets was placed in the friability tester, which was then 
operated for 25 revolutions for 4 min, tablets were dusted and reweighed. The friability 
of the tablets was calculated using the formula mentioned below. 
 
% Friability = 
Initial weight  –  Final weight of the tablets 
x100 
Initial weight of the tablets 
Equation 1 
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6.2.4.5 Drug Content 
 Ten tablets were randomly taken, weighed and powdered. The powder weight 
equivalent to 140mg of Ketoprofen was weighed out and put in 150ml of methanol and 
placed in an ultra sonicator for 5 min. The sonicated solution was then filtered out using 
a Whatman No. 1 filter paper. The filtered solution was then made-up to 250ml using 
methanol. 5ml from the above solution was taken and diluted to 100ml with methanol. 
The final solution was analyzed using U.V. Visible spectrophotometer at 258nm. The 
drug content was computed from the A (1%, 1cm)  (662.0, for Ketoprofen)
(42)
 
6.2.4.6 Swelling Index 
 The, previously weighed (w1), tablets were placed individually in a petri-dish 
containing 10ml of distilled water. The weight of the tablet (w2) after 30min was noted 
down after wiping the excess water from the tablet using a filter paper. The swelling 
index was calculated using the formula
(44)
: 
 
Swelling Index =  
W2  -  W1 
X100 
W1 
Equation 2 
6.2.4.7  Wash-off Test 
The mucoadhesive properties of the tablets were evaluated by wash-off method. 
Pieces of buccal mucosa of goat were mounted on the glass slides provided with suitable 
support. After fixing 2 tablets to this glass slide by pressing them onto the pre-wet tissue 
for 30sec, it was tied to the arm of tablet disintegration test apparatus (with the 
cylindrical drug chambers removed) and was run at 37°C in pH 6.8 buffer. Time taken 
for the detachment of both the tablets was noted down
(20)
. 
6.2.4.8 In vitro drug release study 
The dissolution study was carried out in a dissolution apparatus. The dissolution 
medium consisted of 900ml of pH 6.8 phosphate buffer. The temperature was set at 37 ± 
0.5°C with a rotation speed of 50 rpm. The Ketoprofen buccal tablet was allowed to sink 
to the bottom of the vessel. Samples of 10ml were withdrawn at 10 min interval, filtered 
and analyzed by UV at 260nm.     
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6.2.4.9 Ex vivo drug permeation study 
 The drug release from the formulated tablet was assessed using a Franz diffusion 
cell. The donor and the receptor chambers were separated by goat buccal mucosa. The 
receptor chamber was filled with pH 6.8 phosphate buffer. The temperature was set at 
37 ± 0.5°C. Drug release from the buccal tablets was studied for a period of 1 hour per 
tablet. Samples of 1ml receptor fluid were withdrawn at 15min time interval and diluted 
to 10ml with pH 6.8 buffer solution. They were then analyzed by spectrophotometric 
method at 260 nm
(45)
. 
6.2.4.10 Drug Release Kinetics 
 The release of drugs from the tablet can be characterisedusing various kinetic 
models
(46)
. 
 
 Zero order equation 
The zero order release kinetics can be obtained by plotting cumulative % drug 
released (vs) time (hours). It is ideal for the formulation to have release profile of zero 
order to achieve pharmacological prolonged action. 
 
C = Kot 
Equation 3 
Where, Ko = Zero order constant in conc. / time 
t = Time in hours 
 
 First order equation 
The graph was plotted as log % cumulative drug remaining (vs) time in hours. 
 
Log C = log Co – Kt/2.303 
Equation 4 
Where, 
Co = Initial drug concentration 
K = First order constant 
t = Time in hours. 
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 Higuchi Kinetics 
The graph was plotted with % cumulative drug released (vs) square root of time. 
 
Q = Kt
½
 
Equation 5 
Where, 
K = Constant reflecting design variable system (Differential rate 
constant) 
t = Time in hours. 
The drug release rate is inversely proportional to the square root of time. 
 
 Korsmeyer – Peppas equation 
To evaluate the mechanism of drug release, it was further plotted in Peppas 
equation as log cumulative % of drug released (vs) log time. 
 
Mt/Mα= Kt
n
 
Equation 6 
Where,  
Mt/Mα= Fraction of drug released at time t 
t = Release time 
K = Kinetics constant (Incorporating structural and geometric 
characteristics of the formulation) 
n = Diffusional exponent indicative of the mechanism of drug release. 
 
Table 4.16: Release mechanisms based on n-value 
Diffusion exponent 
(n) 
Overall solute diffusion 
mechanism 
0.45 Fickian diffusion 
0.45 < n < 0.89 Anomalous (non-Fickian) diffusion 
0.89 Case-II transport 
n > 0.89 Super case-II transport 
 
 
The n value obtained is used to characterize different release mechanisms for cylindrical 
shaped matrices. 
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 Hixson and Crowell erosion equation 
To evaluate the drug release with changes in the surface area and the diameter of 
particles, the data were plotted using the Hixson and Crowell erosion equation. The 
graph was plotted by cube root of % drug remaining Vs Time in hours. 
 
 
Qo
⅓
 – Q t
⅓
  =KHCt 
Equation 7 
Where, 
Qt = Amount of drug released at time t 
Qo = Initial amount of drug 
KHC = Rate constant for Hixson Crowell equation 
Table 4.17: Parameters of release kinetics 
Release 
Mechanism 
Y – Axis X - Axis 
Zero-order 
Kinetics 
% Cum. drug 
release 
Time in 
min 
First order 
Kinetics 
Log % cum. drug 
remaining 
Time in 
min 
Higuchi kinetics % cum. drug release 
Square 
root of 
time 
Korsmeyer-Peppas 
Equation 
Log cum.% of drug 
release 
Log time 
Hixson and 
Crowell Equation 
Cube root of % drug 
remaining 
Time in 
min 
 
6.2.4.11 Prediction and optimization 
The results obtained from the wash-off time and ex vivo permeation study were 
selected as the key parameters for optimizing the formulations. The two responses were 
evaluated in an optimization-software: Design Expert
®
 8.0.7.1 issued by Statease. The 
responses were transformed into logarithmic values and analyzed by stepwise 
regression, where in, terms are added to the final response equation in steps by 
evaluating their significance. The predicted responses are compared with the actual 
values and the optimized formulation is set as the one with both good wash-off time and 
ex vivo permeation. 
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7 Results and Discussions 
7.1 Results 
7.1.1 Pre-compressional Evaluations 
 The DSC analysis of the drug and polymer gave thermal profile 
characteristic of the substances. 
 
Figure 7.1: Overlay of DSC profiles of drug and polymers 
 
 The assay of the drug, Ketoprofen showed that the drug was 99.7% pure. 
 The particle size analysis of Ketoprofen is done by sieve method yielded 
the following results – 90.08µm (dave) 
 Solubility of Ketoprofen in pH 6.8 buffer at room temperature (28.5°C) 
was found to be 38.7 mg/ml
(47)
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7.1.2 Ketoprofen - Buccal Tablet Evaluations 
7.1.1.1 Uniformity of Weight: 
The results for the uniformity of weight are tabulated below. 
Table 7.1: Uniformity of Weight 
 
 
 
Note: * Mean ± S.D.(n=20) 
 
 
 
Figure 7.2: Uniformity of Weight 
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S.no. 
Formulation 
Code 
Uniformity of Weight 
(mg)* 
1 DC.5.10.5 71.2 ± 2.16 
2 DC.5.10.20 69.8 ± 1.95 
3 DC.5.40.5 64.6 ± 1.26 
4 DC.5.40.20 72.5 ± 3.86 
5 DC.20.10.5 72.1 ± 1.69 
6 DC.20.10.20 73.8 ± 1.66 
7 DC.20.40.5 69.9 ± 3.52 
8 DC.20.40.20 68.4 ± 1.91 
9 WG.5.10.5 70.7 ± 3.82 
10 WG.5.10.20 69.6 ± 1.45 
11 WG.5.40.5 69.2 ± 1.94 
12 WG.5.40.20 64.6 ± 1.26 
13 WG.20.10.5 70.6 ± 1.95 
14 WG.20.10.20 66.8 ± 1.23 
15 WG.20.40.5 69.5 ± 2.23 
16 WG.20.40.20 70.4 ± 3 
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7.1.1.2 Thickness of the Ketoprofen buccal tablet 
The results for the thickness of the Ketoprofen buccal tablets are tabulated below 
Table 7.2: Average thickness of the Ketoprofen buccal tablets 
S.no. 
Formulation 
Code 
Thickness 
(mm)* 
1 DC.5.10.5 2.3 ± 0 
2 DC.5.10.20 2.26 ± 0.055 
3 DC.5.40.5 2.14 ± 0.055 
4 DC.5.40.20 2.32 ± 0.045 
5 DC.20.10.5 2.22 ± 0.045 
6 DC.20.10.20 2.29 ± 0.055 
7 DC.20.40.5 2.21 ± 0.022 
8 DC.20.40.20 2.17 ± 0.067 
9 WG.5.10.5 2.25 ± 0.05 
10 WG.5.10.20 2.24 ± 0.055 
11 WG.5.40.5 2.21 ± 0.022 
12 WG.5.40.20 2.21 ± 0.022 
13 WG.20.10.5 2.26 ± 0.055 
14 WG.20.10.20 2.25 ± 0.05 
15 WG.20.40.5 2.25 ± 0.05 
16 WG.20.40.20 2.25 ± 0.05 
 
Note:* Mean ± S.D. (n=10) 
 
 
Figure 7.3: Average thickness of the Ketoprofen buccal tablets 
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7.1.1.3 Hardness of the Ketoprofen buccal tablets: 
The results for the hardness of the Ketoprofen buccal tablets are tabulated below   
Table 7.3: Average hardness of the Ketoprofen buccal tablets 
 
S.no. 
Formulation 
Code 
Average 
Hardness 
(kP)* 
1 DC.5.10.5 2.4 ± 0.06 
2 DC.5.10.20 2.4 ± 0.06 
3 DC.5.40.5 2.4 ± 0 
4 DC.5.40.20 2.4 ± 0.06 
5 DC.20.10.5 2.5 ± 0 
6 DC.20.10.20 2.5 ± 0 
7 DC.20.40.5 2.4 ± 0.06 
8 DC.20.40.20 2.4 ± 0.06 
9 WG.5.10.5 2.4 ± 0.06 
10 WG.5.10.20 2.4 ± 0.06 
11 WG.5.40.5 2.4 ± 0.06 
12 WG.5.40.20 2.4 ± 0.06 
13 WG.20.10.5 2.4 ± 0.06 
14 WG.20.10.20 2.4 ± 0 
15 WG.20.40.5 2.4 ± 0 
16 WG.20.40.20 2.4 ± 0 
 
Note 1:* Mean ± S.D. (n=3) 
 
 
Figure 7.4: Average hardness of the Ketoprofen buccal tablets 
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7.1.1.4 Friability of the Ketoprofen buccal tablets 
The results for the friability test for the Ketoprofen buccal tablets are tabulated 
below 
Table 7.4: % Friability of the Ketoprofen buccal tablets 
 
S.no. 
Formulation 
Code 
% Friability 
1 DC.5.10.5 0.4740 
2 DC.5.10.20 0.1164 
3 DC.5.40.5 0.0000 
4 DC.5.40.20 0.8700 
5 DC.20.10.5 0.7760 
6 DC.20.10.20 0.6009 
7 DC.20.40.5 0.1270 
8 DC.20.40.20 0.0007 
9 WG.5.10.5 0.0004 
10 WG.5.10.20 0.0025 
11 WG.5.40.5 0.2704 
12 WG.5.40.20 0.0013 
13 WG.20.10.5 0.3830 
14 WG.20.10.20 0.0673 
15 WG.20.40.5 0.0025 
16 WG.20.40.20 0.5554 
 
The tablets are within the limits for friability. 
7.1.1.5 Drug content in the Ketoprofen buccal tablets 
The standard solution of Ketoprofen was prepared using pH 6.8 buffer. The 
serial dilutions were then analyzed by UV spectrophotometer at 260nm.   
Table 7.5: Absorbance of standard solutions of Ketoprofen 
 
Concentration 
μg/ml  
Absorbance 
0 0 
15 0.092 
30 0.203 
45 0.298 
60 0.394 
75 0.512 
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Figure 7.5: Standard plot for Ketoprofen @ pH 6.8 
The Ketoprofen buccal tablets were designed to carry a drug load of 12.5mg/tablet. 
Table 7.6: Assay values (%) and drug contents (mg) of the Ketoprofen buccal tablets 
 
S.no. 
Formulation 
Code 
% Assay 
Values 
Drug 
Content 
(mg) 
1 DC.5.10.5 99.9 12.49 
2 DC.5.10.20 99.7 12.46 
3 DC.5.40.5 96.2 12.03 
4 DC.5.40.20 100.9 12.61 
5 DC.20.10.5 100.4 12.55 
6 DC.20.10.20 101.8 12.73 
7 DC.20.40.5 100.3 12.54 
8 DC.20.40.20 98.3 12.29 
9 WG.5.10.5 99.8 12.48 
10 WG.5.10.20 99.2 12.40 
11 WG.5.40.5 98.9 12.36 
12 WG.5.40.20 99.1 12.39 
13 WG.20.10.5 100.2 12.53 
14 WG.20.10.20 97.1 12.14 
15 WG.20.40.5 99.3 12.41 
16 WG.20.40.20 100.5 12.56 
 
 The drug content in various formulations are found to be of satisfactory level. 
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7.1.1.6 Swelling Index 
The swelling indices of the various buccal formulations are tabulated below 
Table 7.7: Swelling index of the Ketoprofen buccal tablets 
 
S.no. 
Formulation 
Code 
Swelling 
Index (%) 
1 DC.5.10.5 0.62 
2 DC.5.10.20 1.15 
3 DC.5.40.5 2.22 
4 DC.5.40.20 6.67 
5 DC.20.10.5 3.57 
6 DC.20.10.20 4.55 
7 DC.20.40.5 1.92 
8 DC.20.40.20 1.01 
9 WG.5.10.5 1.11 
10 WG.5.10.20 0.43 
11 WG.5.40.5 1.00 
12 WG.5.40.20 2.10 
13 WG.20.10.5 0.25 
14 WG.20.10.20 2.04 
15 WG.20.40.5 1.00 
16 WG.20.40.20 0.44 
 
 
Figure 7.6: Swelling index of the Ketoprofen buccal tablets 
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7.1.1.7 Wash-off test 
The data from the Wash off test are tabulated below. 
Table 7.8: Time duration of attachment of the Ketoprofen buccal tablets 
S.no. 
Formulation 
Code 
Attachment 
Time (min) 
1 DC.5.10.5 15 
2 DC.5.10.20 10 
3 DC.5.40.5 12 
4 DC.5.40.20 20 
5 DC.20.10.5 23 
6 DC.20.10.20 21 
7 DC.20.40.5 24 
8 DC.20.40.20 18 
9 WG.5.10.5 6 
10 WG.5.10.20 8 
11 WG.5.40.5 5 
12 WG.5.40.20 14 
13 WG.20.10.5 10 
14 WG.20.10.20 16 
15 WG.20.40.5 11 
16 WG.20.40.20 18 
 
Note 2: 0-10 min > Poor adhesion strength; 10-30min > Low adhesion strength 
 
 
Figure 7.7:Time duration of attachment of the Ketoprofen buccal tablets 
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7.1.1.8 In vitro drug release study 
 
Table 7.9: In vitro drug release profile of Ketoprofen buccal tablet formulations 1-4 
 
Formulation 
Code 
DC.5.10.5 DC.5.10.20 DC.5.40.5 DC.5.40.20 
Time (min) % Drug Released 
0 0 0 0 0 
10 89.4 84.6 90.3 91.9 
20 97.3 98.1 99.4 98.7 
30 99.1 99.3 99.5 99.6 
40 99.7 99.8 99.7 99.6 
50 - - - - 
60 - - - - 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.8: In vitro dissolution profiles of Ketoprofen buccal tablet formulations 1-4 
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Table 7.10: In vitro drug release profile of Ketoprofen buccal tablet formulations 5-8 
 
Formulation 
Code 
DC.20.10.5 DC.20.10.20 DC.20.40.5 DC.20.40.20 
Time (min) % Drug Released 
0 0 0 0 0 
10 91.1 91.5 86.3 87.6 
20 99.1 98.6 95.2 97.1 
30 99.6 99.6 98.5 98.3 
40 99.7 99.6 99.7 99.8 
50 - - - - 
60 - - - - 
 
 
 
 
 
 
 
 
 
Figure 7.9: In vitro dissolution profiles of Ketoprofen buccal tablet formulations 5-8 
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Table 7.11: In vitro drug release profile of Ketoprofen buccal tablet formulations 9-12 
 
Formulation 
Code 
WG.5.10.5 WG.5.10.20 WG.5.40.5 WG.5.40.20 
Time (min) % Drug Released 
0 0 0 0 0 
10 82.1 30.2 60.4 72.5 
20 94.4 80.2 88.2 97.7 
30 99.4 96.3 99.6 99.2 
40 99.6 97.2 99.6 99.4 
50 - 99.3 - - 
60 - - - - 
 
 
 
 
 
 
 
 
 
 
Figure 7.10:In vitro dissolution profiles of Ketoprofen buccal tablet formulations 9-12 
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Table 7.12:In vitro drug release profile of Ketoprofen buccal tablet formulations 13-16 
 
Formulation 
Code 
WG.20.10.5 WG.20.10.20 WG.20.40.5 WG.20.40.20 
Time (min) % Drug Released 
0 0 0 0 0 
10 10.3 76.2 62.2 32.9 
20 24.2 96.1 90.8 87.4 
30 52.3 98.3 98.4 98.3 
40 95.2 99.7 99.4 99.8 
50 99.4 - - - 
60 - - - - 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.11: In vitro dissolution profiles of Ketoprofen buccal tablet formulations 13-16 
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7.1.1.9 Ex vivo drug permeation study 
The drug permeation data for the various Ketoprofen buccal tablet formulations 
is given below.  
 
 
Table 7.13: Ex vivo drug permeation data for Ketoprofen buccal tablet formulations 1-4 
 
Formulations DC.5.10.5 DC.5.10.20 DC.5.40.5 DC.5.40.20 
Time (min) Amount of drug permeated (%) 
0 0.000 0.000 0.000 0.000 
15 12.982 6.553 3.493 2.874 
30 26.608 13.257 10.012 10.180 
45 33.930 21.021 16.532 12.212 
60 39.635 28.604 23.039 17.065 
 
 
 
 
 
 
 
 
 
 
Figure 7.12: Ex vivo drug permeationfor Ketoprofen buccal tablet formulations 1-4 
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Table 7.14: Ex vivo drug permeation data forKetoprofen buccal tablet formulations 5-8 
 
Formulations DC.20.10.5 DC.20.10.20 DC.20.40.5 DC.20.40.20 
Time (min) Amount of drug permeated (%) 
0 0.000 0.000 0.000 0.000 
15 3.033 10.256 8.547 13.130 
30 5.330 15.926 13.105 16.882 
45 9.499 29.478 17.930 27.021 
60 10.746 32.113 19.316 32.676 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.13: Ex vivo drug permeationfor Ketoprofen buccal tablet formulations 5-8 
 
0.0
5.0
10.0
15.0
20.0
25.0
30.0
35.0
0 15 30 45 60
%
 D
ru
g 
P
er
m
ea
te
d
 
Time (min) 
DC.20.10.5 DC.20.10.20 DC.20.40.5 DC.20.40.20
  
61 
 
 
 
 
 
 
 
Table 7.15: Ex vivo drug permeation data for Ketoprofen buccal tablet formulations 9-12 
 
Formulations WG.5.10.5 WG.5.10.20 WG.5.40.5 WG.5.40.20 
Time (min) Amount of drug permeated (%) 
0 0.000 0.000 0.000 0.000 
15 5.516 3.508 1.852 1.581 
30 8.787 6.885 5.394 3.096 
45 12.614 8.571 8.167 4.577 
60 17.748 11.583 10.318 7.640 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.14: Ex vivo drug permeation for Ketoprofen buccal tablet formulations 9-12 
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Table 7.16: Ex vivo drug permeation data for Ketoprofen buccal tablet formulations 13-16 
 
Formulations WG.20.10.5 WG.20.10.20 WG.20.40.5 WG.20.40.20 
Time (min) Amount of drug permeated (%) 
0 0.000 0.000 0.000 0.000 
15 0.217 1.941 0.783 0.503 
30 0.955 2.220 2.331 0.968 
45 3.406 2.220 5.475 1.461 
60 4.351 2.230 7.821 2.271 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.15: Ex vivo drug permeation for Ketoprofen buccal tablet formulations 13-16 
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7.1.1.10 Drug release kinetics for the buccal tablet formulations 
Table 7.17: Ketoprofen release kinetics and mechanisms from Ketoprofen buccal tablet 
formulations 
Formulation  
R² 
n Release Order 
Release 
Mechanism 
Zero 
Order 
First 
Order 
Higuchi 
Hixon 
Cromwell 
Peppas 
DC.20.10.20 0.9696 0.9699 0.9696 0.9698 0.936 0.175 First order Erosion 
DC.20.10.5 0.9816 0.9817 0.9816 0.9464 0.941 0.19 First order Erosion 
DC.20.40.20 0.9725 0.9751 0.9725 0.9743 0.975 0.139 First order Diffusion 
DC.20.40.5 0.9387 0.9417 0.9387 0.9407 0.923 0.12 First order Erosion 
DC.5.10.20 0.9985 0.9976 0.9985 0.9979 0.968 0.212 Zero order Erosion 
DC.5.10.5 0.9677 0.972 0.9677 0.9706 0.882 0.156 First order Erosion 
DC.5.40.20 0.9747 0.975 0.9747 0.9749 0.839 0.24 First order Erosion 
DC.5.40.5 0.9897 0.9884 0.9897 0.9889 0.933 0.268 Zero order Erosion 
WG.20.10.20 0.951 0.9508 0.951 0.9509 0.933 0.378 Zero order Erosion 
WG.20.10.5 0.9096 0.9093 0.9096 0.9094 0.927 0.446 Zero order Fickian Diffusion 
WG.20.40.20 0.9861 0.9859 0.9861 0.986 0.988 0.214 Zero order Erosion 
WG.20.40.5 0.9542 0.9535 0.9542 0.9537 0.956 0.337 Zero order Diffusion 
WG.5.10.20 0.9873 0.988 0.9873 0.9877 0.936 0.165 First order Erosion 
WG.5.10.5 0.9928 0.9928 0.9928 0.9928 0.994 0.168 Zero order Diffusion 
WG.5.40.20 0.9732 0.9723 0.9732 0.9726 0.989 0.222 Zero order Diffusion 
WG.5.40.5 0.9913 0.9914 0.9913 0.9914 0.893 0.242 First order Erosion 
 
Note 3: For ex vivo permeation study 
 
Figure 7.16: R
2
 values of release kinetics and mechanisms 
 
0.75
0.8
0.85
0.9
0.95
1
1.05
R
2
 V
al
u
e
s 
Formulations 
Zero Order First Order Higuchi Hixson Peppas
  
64 
7.1.1.11 Prediction and Optimization 
Final Equation in Terms of Actual Factors: 
(Wash off Time) 
   
 
Method of preparation Direct Compression 
 
Log10(Wash off Time)  = 
 
1.257960255 
 
 
0.00561609 * HPMCK4M 
 
-0.009720428  * HPMCK100 
 
-0.024291635  * HPMCE50 
 
0.000556938  * HPMCK4M * HPMCK100 
 
0.001068979  * HPMCK4M * HPMCE50 
 
0.001094929  * HPMCK100 * HPMCE50 
 
-5.89503E-05  * HPMCK4M * HPMCK100 * HPMCE50 
   
 
Method of preparation Wet Granulation 
 
Log10(Wash off Time)  = 
 
0.795886981 
 
 
0.00561609 * HPMCK4M 
 
-0.009720428  * HPMCK100 
 
-0.005811862  * HPMCE50 
 
0.000556938  * HPMCK4M * HPMCK100 
 
0.001068979  * HPMCK4M * HPMCE50 
 
0.001094929  * HPMCK100 * HPMCE50 
 
-5.89503E-05  * HPMCK4M * HPMCK100 * HPMCE50 
 
Figure 7.17: Plot of predicted value (vs) actual value for wash-off time 
 
 
 
 
  
65 
Final Equation in Terms of Actual Factors:                  
(Ex vivo Permeation) 
   
     
 
Method of preparation                                                       Direct Compression 
 
 
Log10(Ex vivo permeation in 1h )                                      = 
   
 
                                                          2.054637985 
   
 
-0.064706819  * HPMC K4M 
  
 
-0.014704174  * HPMC K100 
  
 
-0.026930738  * HPMC E50 
  
 
0.001296803  * HPMC K4M * HPMC K100 
 
0.00320541  * HPMC K4M * HPMC E50 
 
 
0.000280888  * HPMC K100 * HPMC E50 
 
-4.14834E-05  * HPMC K4M * HPMC K100 * HPMC E50 
 
 
Method of preparation Wet Granulation 
 
 
Log10(Ex vivo permeation in 1h ) = 
  
 
1.645025056 
   
 
-0.051099913 * HPMC K4M 
  
 
-0.014704174  * HPMC K100 
  
 
-0.011867337  * HPMC E50 
  
 
0.001296803  * HPMC K4M * HPMC K100 
 
-9.95567E-05  * HPMC K4M * HPMC E50 
 
 
0.000280888  * HPMC K100 * HPMC E50 
-4.14834E-05  * HPMC K4M * HPMC K100 * HPMC E50 
    
 
Figure 7.18: Plot of predicted value (vs) actual value for Ex vivo permeation 
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The formulations were optimized for the highest wash-off time and ex vivo permeation 
values. 
The optimized formulation was found to be: DC.20.10.20 
Table 7.18: Parameters of optimized formulation 
Method of 
Preparation 
(%) 
HPMC 
K4M 
(%) 
HPMC 
K100 
(%) 
HPMC 
E50 
Actual 
Wash 
off Time 
(min) 
Actual       
ex vivo 
permeation 
(%) 
Predicted 
Wash off 
Time 
(min) 
Predicted   
ex vivo 
permeation 
(%) 
Direct 
Compression 
20 10 20 21 32.1132 20.3896 32.1081 
 
The formulation DC.20.10.20 follows diffusion cum erosion type of release. 
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7.2 Discussions 
7.2.1 Pre-compressional and Formulation parameters 
 The excipients and the drug Ketoprofen have no interactions(47).  
 They showed their characteristic DSC profiles, Ketoprofen-melting point 
≈95°C; HPMC- transition temperature ≈ 100 – 200°C; and povidone, 
softening point ≈ 150°C , ensuring their identity. 
 The drug assay proved that the Ketoprofen supplied was of 
pharmacopoeial standards. 
 The solubility profile of the drug revealed, it is highly soluble in pH 6.8 
buffer 
(47)
.  
 The particle size determination of the drug, Ketoprofen confirmed that it 
can be used in a direct compression. 
7.2.2 Uniformity of weight 
 Although the Ketoprofen buccal tablets are within the permissible limits for 
weight deviation, (Table 7.1) the extreme variations could have been avoided by careful 
monitoring of the tablet weights during the punching process (in process quality 
control). 
7.2.3 Thickness of the Ketoprofen buccal tablets 
The average thickness (Table 7.2) of the Ketoprofen buccal tablets was found to 
be quite uniform with minimum variation. The thickness of the tablet and hence its total 
weight must be reduced in order to obtain good mucoadhesion, as the mucoadhesive 
property is also dependent on the geometry of the dosage form. 
7.2.4 Hardness and friability of the Ketoprofen buccal tablets: 
 The hardness of the Ketoprofen buccal tablets (Table 7.3)are low, but the 
friability data (Table 7.4) suggests that the tablets are quite robust enough to withstand 
the normal handling. 
7.2.5 Drug content analyses 
All the buccal tablet formulations have quite satisfactory drug content (Table 
7.6) the content could have been more uniform just as in the case of the tablet weights, 
since it depended upon the experience and skill level of the tablet punching machine 
operator.  
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7.2.6 Swelling Index 
Swelling index is an important parameter in judging the mucoadhesion property, 
at least in the initial stages, since water uptake is important for the polymers to uncoil 
and interact with the mucin. The swelling indices of the Ketoprofen buccal tablets 
(Table 7.7) reveals that while the buccal tablet formulations are all made of hydrophilic 
materials, the extent of swelling differs based on the individual tablet composition. The 
swelling indices of the first three formulations are quite low because of the fact that they 
started to disintegrate and lose mass soon after placing them upon the petri-dish. The 
formulations containing higher levels of the polymers HPMC K100 and HPMC E50 
displayed the highest swelling index. The reason for this is because, they are of lower 
viscosity grade and hence the water penetration in to the tablet matrix is facilitated by 
them
(19)
. The tablets prepared by dry granulation showed greater swelling compared to 
the ones made by wet granulation. This could be attributed to the increased cohesion 
between the granules in case of the formulations prepared by wet granulation technique. 
But this is counter intuitive since, the wet granulation technique incorporated PVP K90 
which is hydrophilic polymer and also it contains lesser quantity of Magnesium stearate, 
which is the key hydrophobic excipient in the formulation.      
7.2.7 Wash-off time 
All the formulations displayed low-poor mucoadhesion (Table 7.8). This may be 
attributed to the effect of the filler/diluent material. The presence of MCC in the 
formulation enhanced both the disintegration of the tablet matrix and the deprivation of 
the water molecules for the mucoadhesive polymers. It has been previously discussed 
that a high diluent level reduces the mucoadhesion property of the formulations 
(48)
. The 
poor attachment time can also be attributed to the low concentration of polymer in the 
formulations
(27)
. Barring the effect of the diluent, the other factors that affect the 
attachment time arethe method of preparation. As seen with the previous effect, swelling 
index, direct compression leads to slightly better attachment time. Similarly, the 
presence of high concentration of HPMC K4M aslo contributes to the higher 
mucoadhesion time while the other two grades, K100 and E50 gave a relatively smaller 
negative effect. The dual interactions between the three polymers had a positive effect 
on the wash-off time. The triple interaction of the polymer inflicted a very slight 
negative effect. (as evidenced from the response equation.)    
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7.2.8 In vitro drug release 
All the formulations had good release, >99% within 50min (Table 7.9-7.12). 
This can be attributed to the fact that all the excipients used except the glidant – 
Magnesium stearate, are hydrophilic in nature. The polymers, at their maximum level, 
are only 60% of the drug content. This and the fact that the drug, Ketoprofen has high 
solubility in pH 6.8, contribute to the relatively fast dissolution rate.      
7.2.9 Ex vivo drug permeation 
The release profiles of the various buccal tablet formulations (Table 7.13-7.16) 
reveal that the drug release from the direct compression tablets is at a greater rate than 
from the wet granulation batches. The higher levels of polymers, especially HPMC 
K4M retarded the release from the buccal tablet. This is evident from the equation for 
the ex vivo permeation, the coefficient for HPMC K4M is the largest – signifying that it 
is the major contributor while the coefficients of K100 and E50 are relatively smaller. 
The dual interactions between the polymers, however, were conducive of drug 
permeation and therefore, drug release. The three way interaction between the polymers 
gave a relatively smaller negative contribution to the response, ex vivo permeation.    
7.2.10 Drug release kinetics 
The drug release kinetics is predominantly first order for the Ketoprofen buccal 
tablets manufactured by direct compression method and predominantly zero for those 
manufactured by wet granulation method (Table 7.17). The release mechanism was 
found to be Fickian diffusion coupled with erosion of the tablet matrix. The diffusion is 
attributed to the presence of HPMC polymer (high viscosity – K4M) and the erosion is 
primarily due to the rapidly hydrating MCC and low viscosity HPMC polymers, K100 
and E50.  
7.2.11 Prediction and optimization 
The predicted values of response were in agreement with the actual values. 
Hence this model can be adapted to study the effects of the different formulation 
parameters. Furthermore, the model can be used to predict globalized responses after apt 
experimentation. 
  
 
 
 
  
 
 
 
 
 
 
SUMMARY  
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8 Summary  
 
In the present work, effect of different formulation and process variables, method 
of preparation – direct compression or wet granulation, different levels of HPMC K4M, 
HPMC K100 and HPMC E50, on the buccal tablets of Ketoprofen were studied. The 
buccal tablet formulations were determined by the 2-full factorial experimental design – 
2
n,
 where, n is the number of independent variables. Ketoprofen buccal tablets can be of 
great help to geriatric patients on anti-hypertensive treatment who suffer from tooth 
ache. 
 The different grades of the polymer HPMC – (K4M, K100, E50) were used as 
the buccal-adhesive polymers. 
 The buccal tablets were tested for weight uniformity, thickness, friability and 
hardness. 
 They were then evaluated for their swelling index, in vitro drug release, wash-off 
time – indirect measure of adhesion strength, and ex vivo drug permeation. 
 The kinetics and mechanism of the drug permeation through the excised buccal 
tissue of goat from the buccal tablets were also characterized. 
 The data collected were then analyzed using software to determine the effects of 
each parameter. 
 The effects of the various parameters involved were then interpreted. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
CONCLUSION 
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9 Conclusion 
 
Ketoprofen buccal tablets were manufactured by both direct compression method 
and wet granulation method using different levels and combinations of the polymers 
HPMC K4M, K100 and E50. Solubility of Ketoprofen was determined - 38.7 mg/ml in 
pH 6.8 buffer by equilibrium solubility method. 2
4 
full Factorial design showed that the 
direct compression method was suitable for the preparation of Ketoprofen buccal tablets. 
The prepared buccal tablets’ physical characteristics were evaluated and they complied 
with the official pharmacopoeial limits. The in vitro dissolution results revealed that the 
drug release was more than 95% within 45min, suggesting high solubility of Ketoprofen 
in pH 6.8 buffer. The Wash-off time of the tablets gave an indirect measure of their 
mucoadhesive property. The step-wise regression equation indicates that the polymers 
interact in multiple ways. But the method of preparation and the presence of low 
viscosity polymers had the greatest effect on this property. The ex vivo permeation study 
indicated the drug was highly permeable (≈40% within 1 hour). The polymer interaction 
contributed positively in two-way interactions and was negative in case of three-way 
interactions. The contribution of the individual polymers had shown negative effect. 
Therefore the formulation - DC.20.10.20, had the optimum response values among all 
the formulations. Hence, it can be considered for further study. 
Given the ease of manufacture of the dosage form and the extensive data 
available on the drug candidate, the formulation can be considered for marketing in the 
near future after suitable studies. 
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